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ABSTRACT	  	  
HISTONE	  DEACETYLASE	  INHIBITORS	  TRICHOSTATIN	  A	  (TSA)	  AND	  
SULFORAPHANE	  (SFN)	  MODULATE	  VITAMIN	  D	  RESPONSIVE	  CYP24	  GENE	  
	  EXPRESSION	  IN	  3T3-­‐L1	  PREADIPOCYTES	  	  SEPTEMBER	  2013	  	  EUNJEE	  AHN,	  B.S.,	  CHUNGNAM	  NATIONAL	  UNIVERSITY	  	  M.S.	  UNIVERSITY	  OF	  MASSACHUSETTS,	  AMHERST	  	  Directed	  by:	  Professor	  RICHARD	  WOOD	  	  	  	   Vitamin	   D	   plays	   an	   important	   role	   in	   preserving	   healthy	   bones,	   and	   has	  additional	   roles	   in	   the	   body,	   including	   modulation	   of	   cell	   growth,	   differentiation,	  neuromuscular	  and	  immune	  function,	  and	  anti-­‐inflammatory	  function.	  The	  vitamin	  D	   receptor	   (VDR)	   is	   a	  member	   of	   the	   nuclear	   hormone	   receptor	   superfamily	   and	  regulates	  transcription	  of	  vitamin	  D-­‐dependent	  target	  genes,	  such	  as	   those	   for	  key	  proteins	   involved	   in	   calcium	   and	   phosphorus	   absorption	   and	   bone	   development.	  Histone	  acetylation	  weakens	  the	  association	  of	  histones	  with	  DNA,	  and	  increases	  the	  accessibility	  of	  transcriptional	  regulatory	  proteins	  to	  chromatin	  templates,	  thereby	  increasing	  transcriptional	  activity	  of	  gene	  expression.	  Histone	  deacetylases	  remove	  the	   acetyl	   groups	   and	   condense	   chromatin	   structure,	   thereby	   preventing	  transcription.	   TSA	   is	   a	   potent	   histone	   deacetylase	   inhibitor	   and	   can	   significantly	  enhance	  gene	  expression.	  Bioactive	  food	  component,	  sulforaphane	  (SFN)	  is	  found	  in	  cruciferous	  vegetables	  and	  is	  known	  to	  be	  a	  histone	  deacetylase	  inhibitor,	  leading	  to	  transcriptional	   activation	   of	   gene	   expression.	   The	   objective	   of	   this	   study	   is	   to	  demonstrate	   that	   the	   bioactive	   food	   components	   modulate	   vitamin	   D	   action	   in	  adipocytes.	  To	  investigate	  the	  effects	  of	  TSA	  and	  SFN	  on	  vitamin	  D	  response,	  3T3L1	  
	  vi	  
mouse	  preadipocytes	  were	  treated	  with	  the	  combination	  of	  various	  concentrations	  of	   1,25(OH)2	   vitamin	  D,	  TSA,	   and	   SFN.	   	  Upon	  harvesting	   cells,	   the	   amounts	   of	   24-­‐hydroxylase	   mRNA,	   marker	   of	   vitamin	   D	   response,	   were	   measured	   by	  semiquantitative	   reverse	   transcriptase-­‐PCR	   analysis.	   The	   results	   showed	   that	   the	  cells	   treated	  with	  1μM	  TSA	   increased	  1,25(OH)2	   	  vitamin	  D-­‐induced	  CYP24	  mRNA	  level	  nearly	  3.5-­‐fold	  (p	  <	  0.05)	  at	  1nM	  1,25(OH)2	  vitamin	  D	  and	  nearly	  2.5-­‐fold	  (p	  <	  0.05)	  in	  10	  nM	  1,25(OH)2	  vitamin	  D,	  and	  the	  cells	  treated	  with	  5μM	  SFN	  increased	  1,25(OH)2	  	  vitamin	  D-­‐induced	  CYP24	  mRNA	  level	  nearly	  1.4-­‐fold	  at	  1nM	  1,25(OH)2	  vitamin	  D	  and	  nearly	  1.2-­‐fold	  at	  10	  nM	  1,25(OH)2	  vitamin	  D.	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1.1	  Introduction	  Vitamin	  D	  is	  produced	  in	  the	  skin	  in	  response	  to	  UVB	  radiation	  and	  is	  found	  in	   a	   limited	   number	   of	   foods.	   Vitamin	   D	   status	   plays	   an	   important	   role	   in	  maintaining	   healthy	   bones	   by	   promoting	   calcium	   absorption	   in	   the	   gut	   and	  maintaining	   adequate	   serum	   calcium	   and	   phosphate	   concentrations.	   	   Serum	   25-­‐hydroxyvitamin	   D	   concentration	   reflects	   vitamin	   D	   exposure.	   Low	   serum	   25-­‐hydroxyvitamin	  D	  concentrations	  are	  associated	  with	  low	  bone	  mineral	  density	  and	  fractures,	  while	   sufficient	   serum	  25-­‐hydroxyvitamin	  D	   concentrations	   can	  prevent	  rickets	  in	  children,	  osteomalacia	  in	  adults,	  and	  osteoporosis	  in	  older	  adults.	  Vitamin	  D	   also	   has	   other	   roles	   in	   the	   body,	   including	   modulation	   of	   cell	   growth,	  differentiation,	   neuromuscular	   and	   immune	   function,	   and	   anti-­‐inflammatory	  function.	  The	  vitamin	  D	  receptor	  (VDR)	  is	  a	  member	  of	  the	  nuclear	  hormone	  receptor	  superfamily	   and	   regulates	   transcription	   of	   vitamin	   D-­‐dependent	   target	   genes.	  	  Nuclear	   receptors	   act	   as	   ligand-­‐inducible	   transcription	   factors	   and	   interact	   with	  DNA	  response	  elements	  of	  target	  genes	  (Aranda	  and	  Pascual,	  2001).	  Upon	  activation	  by	   the	   active	   1,25-­‐dihydroxyvitamin	   D	   metabolite,	   the	   VDR	   binds	   to	   vitamin	   D	  response	   elements	   (VDREs)	   on	   the	   DNA	   of	   target	   genes,	   such	   as	   those	   for	   key	  proteins	  involved	  in	  calcium	  and	  phosphorus	  absorption	  and	  bone	  development.	  	  	  
	  	   2	  
	  
	   	  	   Within	   the	   nucleus,	   chromatin	   represents	   DNA	   that	   is	   wrapped	   around	  histone	  protein	  complexes	  to	  form	  nucleosomes	  (Figure	  1).	  Chromatin	  structure	  can	  be	   modified	   by	   altering	   the	   binding	   affinity,	   which	   is	   controlled	   by	   the	   opposing	  activities	  of	  histone	  acetyltransferases	  (HATs)	  and	  histone	  deacetylases	  (HDACs),	  of	  DNA	   to	   histone	   proteins.	   Histone	   acetylation	  weakens	   the	   association	   of	   histones	  with	   DNA,	   thereby	   altering	   nucleosomal	   conformation	   and	   increasing	   the	  accessibility	  of	  transcriptional	  regulatory	  proteins	  to	  chromatin	  templates.	  (Norton	  et	   al.,	   1989).	   As	   a	   consequence,	   transcriptional	   activity	   of	   gene	   expression	   may	  increase.	   Histone	   deacetylases	   remove	   the	   acetyl	   groups,	   thereby	   increasing	   the	  positive	   charge	  of	  histone	   tails	   and	  encouraging	  high-­‐affinity	  binding	  between	   the	  histones	   and	   DNA	   backbone.	   The	   increased	   DNA	   binding	   to	   histone	   protein	  condenses	   chromatin	   structure	   and	   prevents	   transcription	   (Struhl,	   1998).	   Certain	  
Figure	  1	  Modulation	  of	  chromatin	  conformation	  and	  transcriptional	  status	  by	  acetylation	  of	  lysine	  residues	  in	  histones.	  HDAC,	  histone	  deacetylase;	  HAT,	  histone	  acetyltransferase	  (Ho	  et	  al.,	  2009)	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chemicals	  have	  been	  found	  that	  can	  alter	  HDAC	  activity,	  such	  as	  trichostatin	  A	  (TSA).	  TSA	   is	   an	   organic	   antifungal	   antibiotic	   that	   is	   a	   potent	   inhibitor	   of	   the	   histone	  deacetylase	   (Yoshida	   et	   al.,	   1990)	   and	   can	   significantly	   enhance	   gene	   expression	  (Nan	  et	  al.,	  2004).	  	  For	  example,	  a	  study	  by	  Luo	  et	  al.	  demonstrated	  that	  inhibition	  of	  histone	  deacetylases	  by	  TSA	  increases	  the	  expression	  of	  vitamin	  D	  24-­‐hydroxylase	  (CYP24A1)	  in	  prostate	  cancer	  cells	  (Luo	  et	  al.,	  2010).	  	  	   Certain	   plant	   foods	   contain	   bioactive	   food	   components	   that	   may	   be	  important	   for	   optimal	   health.	   Bioactive	   food	   components	   refer	   to	   nonessential	  biomolecules	  with	  biological	  activity	  that	  is	  predominantly	  found	  in	  plant	  foods	  such	  as	  whole	  grains,	   fruits,	   and	  vegetables.	  A	  diet,	   rich	   in	  nutrients	  and	  bioactive	   food	  components	  may	  play	  a	  vital	  role	  in	  improving	  health	  and	  reducing	  risk	  for	  chronic	  disease	   (Liu,	   2003).	   	   In	   recent	   years,	   bioactive	   food	   components	   are	   being	  intensively	   studied	   to	   evaluate	   their	   effects	   on	   health.	   An	   underlying	   mechanism	  through	  which	  some	  bioactive	  food	  components	  may	  affect	  health	  is	  by	  influencing	  gene	  expression	  by	  altering	   epigenetic	   “marks”	   (methylation	  and	  acetylation)	   that	  control	  DNA	  access.	  For	  example,	  the	  bioactive	  food	  component	  sulforaphane	  (SFN)	  is	  found	  in	  cruciferous	  vegetables,	  such	  as	  broccoli	  and	  cauliflower,	  and	  is	  known	  to	  have	   histone	   deacetylase	   inhibitor	   activity	   (Myzak	   et	   al.,	   2004),	   which	   promotes	  hyperacetylation	   of	   chromatin	   and	   affects	   the	   expression	   of	   genes,	   leading	   to	  transcriptional	  activation	  of	  some	  genes	  (Struhl,	  1998).	  Recent	  studies	  have	   found	  that	  epigenetic	  changes	  can	  lead	  to	  an	  increase	  in	  the	  expression	  of	  some	  genes	  and	  a	  decrease	  in	  the	  expression	  of	  others.	  Moreover,	  interestingly,	  only	  small	  subsets	  of	  genes	   are	   apparently	   affected	   by	   these	   epigenetic	   alterations,	   and	   these	   changes	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appear	  also	   to	  be	   tissue	  specific.	  The	   identification	  of	  which	   tissues	  and	  genes	  are	  affected	  by	  various	  bioactive	  food	  components	  and	  how	  these	  changes	  affect	  health	  is	  a	  new	  and	  growing	  area	  of	  nutritional	  research.	  	  
1.2	  Vitamin	  D	  
1.2.1	  Production	  
	  	   Vitamin	   D	   is	   a	   fat-­‐soluble	   vitamin	   that	   is	   naturally	   present	   in	   only	   a	   small	  number	   of	   foods,	   but	   is	   produced	   endogenously	   in	   the	   skin	   by	   UVB	   irradiation	  between	  290-­‐315	  nm.	  The	  two	  major	  forms	  of	  vitamin	  D,	  which	  differ	  chemically	  in	  their	  side	  chains,	  are	  cholecalciferol	  and	  ergocalciferol.	  Cholecalciferol	   is	  known	  as	  vitamin	   D3	   and	   is	   produced	   in	   animals	   from	   cutaneous	   7-­‐dehydrocholesterol	   (7-­‐DHC),	  while	   ergocalciferol	   is	   known	  as	   vitamin	  D2	   and	   is	  produced	   in	  plants	   from	  ergosterol,	   a	   plant	   sterol	   (Figure	   2).	   Vitamin	   D3	   is	   translocated	   from	   the	   skin	   to	  bloodstream,	  bound	  in	  plasma	  to	  the	  vitamin	  D	  binding	  protein.	  	   	   	  	  	  
Figure	   2	   Production	   of	   vitamin	   D2	   and	   vitamin	   D3:	   Photolysis	   of	   ergosterol	   in	   plants	   (a)	   and	   7-­‐dehydrocholesterol	   (b)	   in	   skin	   7-­‐DHC	   to	   previtamin	   D2	   (pre-­‐D2)	   and	   previtamin	   D3	   (pre-­‐D3)	   and	  their	   thermal	   isomerizations	   to	   vitamin	   D2	   (ergocalciferol)	   and	   vitamin	   D3	   (cholecalciferol),	  respectively.	  D2	  and	  D3	  differ	  only	  in	  the	  side	  chain	  in	  which	  D2	  has	  a	  double	  bond	  between	  C22–C23	  and	  a	  methyl	  group	  at	  C24	  (Bikle,	  2010).	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Vitamin	  D	  synthesized	  from	  sun	  exposure,	  or	  obtained	  from	  dietary	  sources	  is	   biologically	   inert	   and	   must	   undergo	   two	   hydroxylations	   to	   become	   the	   active	  hormone	  form	  (Figure	  3).	  	  	  	   	  
Figure	  3	  Overview	  of	  vitamin	  D	  synthesis,	  intake,	  and	  activation	  (	  http://www.nap.edu	  /openbook.php?record_id=13050&page=76)	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   The	  first	  hydroxylation	  occurs	  in	  the	  liver	  due	  to	  the	  action	  of	  a	  P450	  enzyme	  coded	   by	   the	   cyp2r1	   gene	   and	   converts	   vitamin	   D	   to	   25-­‐hydroxyvitamin	   D	  (25(OH)D3)	   known	   as	   calcidiol	   (Figure	   3).	   The	   second	   hydroxylation	   occurs	  primarily	  in	  the	  kidney	  due	  to	  the	  action	  of	  the	  P450	  enzyme	  (25-­‐hydroxyvitamin	  D	  1α-­‐hydroxylase),	   coded	  by	   the	   cyp27b1	   gene,	   and	   forms	   the	  physiologically	   active	  1,25-­‐dihydroxyvitamin	  D	  (1,25(OH)2D3)	  metabolite	  known	  as	  calcitriol.	  This	  vitamin	  D	  metabolite	   is	   the	  hormonal	   form	  of	  vitamin	  D	   that	   is	   responsible	   for	  most	  of	   its	  biological	   functions	   (Figure	   3).	   The	   production	   of	   1,25(OH)2D3	   in	   the	   kidney	   is	  stimulated	   and	   tightly	   controlled	   by	   parathyroid	   hormone	   (PTH)	   and	   plasma	  phosphate	  concentration,	  which	  enhances	  the	  activity	  of	  renal	  1α-­‐hydroxylase,	  and	  is	   inhibited	   by	   raised	   plasma	   calcium	   and	   phosphate	   concentration.	   The	   1α-­‐hydroxylase	   is	   also	   inhibited	   by	   fibroblast	   growth	   factor	   23	   (FGF23),	   which	   is	  produced	   in	   bone	   cells.	   CYP24A1	   gene	   encodes	   24-­‐hydroxylase	   that	   catalyzes	   the	  conversion	   of	   25-­‐hydroxyvitamin	   D3	   and	   1,25-­‐dihydroxyvitamin	   D3	   into	   24-­‐hydroxylated	  products,	  which	  constitute	  the	  degradation	  of	  the	  vitamin	  D	  molecule	  (Beckman	  et	  al.,	  1996,	  Holick,	  2010).	  
	  
1.2.2	  Absorption,	  transport	  and	  metabolism	  Being	  fat-­‐soluble,	  dietary	  vitamin	  D	  (both	  D2	  and	  D3)	  is	  mixed	  with	  other	  fats	  and	  incorporated	  with	  the	  aid	  of	  bile	  salts	  into	  micelles	  in	  the	  small	  intestine	  from	  which	   it	   is	   absorbed	   and	   enters	   mucosal	   enterocytes	   by	   passive	   diffusion.	   Once	  absorbed,	   it	   is	   incorporated	   into	   chylomicrons,	  which	   are	   released	  by	   enterocytes	  and	   enter	   the	   lymphatic	   system.	   Lymphatic	   circulation	   transfers	   vitamin	   D	   in	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chylomicrons	   into	   the	   blood	   stream.	   After	   vitamin	   D	   in	   chylomicron	   reaches	   the	  liver,	   25-­‐hydroxylation	   can	   occur	   and	   the	   25-­‐hydroxyvitamin	   D	   metabolite	  produced	  is	  attached	  to	  plasma	  vitamin	  D	  binding	  protein	  (DBP).	  Vitamin	  D	  binding	  protein	  and	  albumin	  are	  the	  primary	  transporters	  of	  vitamin	  D	  metabolites	  in	  blood	  (Wildman,	  2011,	  SarDesai,	  2012).	  	  Since	   serum	   25-­‐hydroxyvitamin	   D	   (25(OH)D3)	   	   is	   the	   predominant	  circulating	  form	  of	  vitamin	  D	  in	  the	  blood	  and	  increases	  in	  proportion	  to	  vitamin	  D	  intake	  and	  sunlight	  exposure,	  it	  is	  measured	  in	  the	  blood	  to	  determine	  the	  vitamin	  D	  status	   (Anderson	   et	   al.,	   2003).	   The	  unbound	   form	  of	   25(OH)D3	   enters	   the	   kidney,	  where	   a	   second	   hydroxylation	   can	   occur	   by	   1α-­‐hydroxylase	   activity	   (25-­‐hydroxyvitamin	   D-­‐1α-­‐hydroxylase,	   CYP27B1)	   forming	   the	   physiologically	   active	  1,25-­‐dihydroxyvitamin	   D	   (1,25(OH)2D3).	   Enzyme	   activity	   of	   CYP27B1	   is	  predominant	  in	  the	  kidney,	  but	  is	  present	  in	  a	  number	  of	  non-­‐renal	  tissues	  and	  cells,	  such	   as	   immune	   cells,	   pancreatic	   cells,	   muscle	   cells,	   adipocytes,	   etc.	   1,25-­‐dihydroxyvitamin	  D	   is	   the	  hormonal	   form	  of	  vitamin	  D	  responsible	   for	  most	  of	   its	  biological	   functions	   via	   its	   ability	   to	   activate	   the	   vitamin	   D	   receptor,	   a	   nuclear	  steroid	   hormone	   transcription	   factor.	   The	   production,	   which	   is	   controlled	   by	  parathyroid	  hormone,	  of	  1,25(OH)2D3	  from	  25(OH)D3	  in	  the	  kidney	  acts	  to	  raise	  the	  serum	  calcium	  level	  to	  normal	  physiological	  range	  by	  stimulating	  intestinal	  calcium	  absorption	   via	   an	   increased	   expression	   of	   calcium	   transport	   proteins,	   such	   as	  TRPV6	   and	   calbindin	  D.	   Low	  blood	   calcium	   level	   is	   associated	  with	   the	   increased	  release	  of	  parathyroid	  hormone	  from	  the	  parathyroid	  glands.	  In	  addition	  to	  its	  effect	  on	  1α-­‐hydroxylase	  to	  produce	  1,25(OH)2D3,	  parathyroid	  hormone	  can	  stimulate	  the	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release	  of	  calcium	  from	  bone	  and	  increase	  renal	  calcium	  reabsorption	  by	  increasing	  the	  activity	  of	  TRPV5	  in	  the	  renal	  distal	  convoluted	  tubule.	  The	   C-­‐24	   oxidation	   pathway	   plays	   a	   major	   role	   in	   the	   biodegradation	   of	  vitamin	   D	   metabolites	   in	   kidney	   (Figure	   3)	   and	   other	   target	   tissues,	   and	   24-­‐hydroxylase	   (1,25(OH)2D3-­‐24-­‐hydroxylase,	   CYP24)	   functions	   in	   the	   catabolism	   of	  1,25(OH)2D3	   (Beckman	   et	   al.,	   1996,	   Holick,	   2010).	   24-­‐hydroxylase	   converts	  25(OH)D	   to	   24,25	   dihydroxyvitamin	   D	   (24,25(OH)2D)	   or	   1,25(OH)2D	   to	   1,24,25	  trihydroxyvitamin	  D	  (1,24,25(OH)3D).	  This	  hydroxylation	  is	  the	  first	  step	  of	  the	  C-­‐24	  oxidation	   pathway,	   which	   catabolizes	   vitamin	   D	  metabolites	   to	   the	   water-­‐soluble	  calcitroic	  acid	  for	  its	  excretion	  by	  the	  kidney	  (Makin	  et	  al.,	  1989,	  Reddy	  and	  Tserng,	  1989).	  Although	  CYP24	  is	  highly	  expressed	  in	  the	  kidney	  tubule,	  it	  is	  also	  distributed	  in	  tissues	  including	  the	  intestine,	  osteoblasts,	  placenta,	  keratinocytes,	  and	  prostate.	  In	  general,	  CYP24	  appears	  to	  be	  found	  wherever	  there	  is	  vitamin	  D	  receptor	  (VDR),	  which	  elicits	  the	  action	  of	  1,25(OH)2D3.	  Overproduction	  of	  1,25(OH)2D3	  is	  regulated	  by	  a	  negative	  feedback	  mechanism,	  in	  that	  1,25(OH)2D3	  inhibits	  PTH	  synthesis	  and	  induces	   24-­‐hydroxylase	   (CYP24A1)	   activity,	   which	   catabolizes	   1,25(OH)2D3	   by	  hydroxylation	   on	   C24.	   Thus	   the	   biological	   activity	   of	   1,25-­‐dihydroxyvitamin	   D	  (1,25(OH)2D3)	  in	  a	  cell	  is	  determined	  mainly	  by	  the	  combination	  of	  the	  level	  of	  VDR	  expression	  and	  the	  local	  24-­‐hydroxylase	  activity	  (Anderson	  et	  al.,	  2003).	  However,	  other	  cellular	  factors	  may	  subsequently	  modulate	  vitamin	  D	  action	  by	  altering	  VDR	  genomic	  activity	  in	  the	  nucleus,	  such	  as	  epigenetic	  factors	  that	  influence	  chromatin	  structure.	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1.2.3.	  Genomic	  actions	  
1.2.3.1.	  Calcemic	  functions	  	   Production	   and	   accumulation	  of	   1,25(OH)2D3	   is	   regulated	   either	  directly	   or	  indirectly	  by	  serum	  calcium	  concentration,	  and	  	  the	  major	  function	  of	  1,25(OH)2D3	  is	  to	   increase	   the	   efficiency	   of	   intestinal	   calcium	   absorption,	   thereby	   increasing	   the	  	  availability	   of	   dietary	   calcium.	   As	   mentioned	   above,	   parathyroid	   hormone	   is	   the	  primary	  hormonal	  factor	  in	  determining	  synthesis	  of	  1,25(OH)2D3	  in	  response	  to	  the	  concentration	  of	  free	  circulating	  calcium	  concentration	  (Garabedian	  et	  al.,	  1972).	  A	  drop	  in	  serum	  calcium	  concentration	  leads	  to	  induction	  of	  synthesis	  and	  secretion	  of	  parathyroid	   hormone,	   which	   then	   acts	   in	   the	   kidney	   to	   stimulate	   transcellular	  calcium	  reabsorption	  and	  in	  bone	  to	  stimulate	  osteoclast	  biogenesis	  (Thomas	  et	  al.,	  2001)	  and	  osteoclast	  bone-­‐resorptive	  function.	  Calcium	  homeostasis	  in	  the	  blood	  is	  maintained	   by	   the	   coordinated	   regulation	   of	   intestinal	   calcium	   absorption,	  mobilization	   of	   calcium	   from	   bone,	   and	   renal	   reabsorption	   of	   calcium	   (DeLuca,	  1981).	   Once	   these	   functions	   return	   serum	   calcium	   to	   normal,	   then	   1,25(OH)2D3	  exerts	   a	   negative	   feedback	   signal	   on	   the	   parathyroid	   glands	   to	   suppress	   further	  synthesis	  and	  secretion	  of	  PTH	  (Cantley	  et	  al.,	  1985,	  Szabo	  et	  al.,	  1989).	  1,25(OH)2D3	  also	  stimulates	  production	  of	  fibroblast	  growth	  factor	  (FGF23),	  produced	  primarily	  by	   bone	   by	   osteoblasts	   and	   osteocyte,	   and	   negatively	   control	   its	   own	   levels	   by	  reducing	  renal1α-­‐hydroxylase	  (Kolek	  et	  al.,	  2005)	  (Figure	  3).	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1.2.3.2.	  Noncalcemic	  functions	  The	  noncalcemic	  functions	  of	  1,25-­‐dihydroxyvitamin	  D	  include	  regulation	  of	  cell	  proliferation	  and	  differentiation,	  hormone	  secretion,	  and	  immunomodulation.	  A	  wide	   number	   of	   tissues	   and	   cells	   including	   the	   brain,	   gonads,	   pituitary	   gland,	  thymus,	   pancreas,	   stomach,	   breast,	   skin,	   adipocytes	   and	   lymphocytes	   possess	  vitamin	  D	   receptor	   (VDR)	   (Holick,	  1995).	  The	  expression	  of	  VDRs	   in	   these	   tissues	  and	  cells	  suggests	  that	  they	  must	  serve	  functions	  there.	  Proliferation	   and	  differentiation	   of	   normal	   and	   cancerous	   cells	   are	   affected	  by	   1,25(OH)2D3	   through	   directly	   or	   indirectly	   altering	   the	   transcription	   of	   cell	  regulatory	   genes,	   as	   the	   inhibition	   of	   the	   growth	   and	   differentiation	   of	   cancer	   by	  	  actions	  of	  1,25(OH)2D3	  was	  shown	  in	   leukemia	  and	  melanoma	  cells	  (Colston	  et	  al.,	  1981).	   Studies	   have	   shown	   that	   vitamin	   D	   inhibits	   adipogenesis	   by	   playing	   an	  important	  role	  in	  the	  cell	  growth	  and	  differentiation	  (Ishida	  et	  al.,	  1988,	  Kong	  and	  Li,	  2006,	  Wood,	  2008).	  	  1,25(OH)2D3	   has	   direct	   effects	   on	   the	   pancreatic	   islet	   cells	   and	   stimulates	  insulin	   secretion	   (Lee	   et	   al.,	   1994).	   VDR	   and	   calbindin-­‐D28k,	   which	   was	   the	   first	  known	   target	   of	   vitamin	   D	   action	   and	   is	   a	   member	   of	   a	   family	   of	   high	   affinity	  calcium-­‐binding	  proteins,	  are	  found	  in	  pancreatic	  beta	  cells	  (Morrissey	  et	  al.,	  1975).	  Calbindin-­‐D28k	  can	  modulate	  depolarization-­‐stimulated	  insulin	  release	  (Sooy	  et	  al.,	  1999)	   and	  protect	   beta	   cells	   against	   cytokine	  mediated	  destruction.	   	  A	  number	  of	  studies	  have	   suggested	   that	   vitamin	  D	  deficiency	   contributes	   to	   increased	   risk	   for	  type	  2	  diabetes	  mellitus	  (Bikle,	  2009,	  Baz-­‐Hecht	  and	  Goldfine,	  2010).	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1,25(OH)2D3	   is	   a	   potent	   immune	   system	   modulator	   and	   can	   help	   in	  suppression	   of	   certain	   autoimmune	   diseases	   and	   cancers	   	   (DeLuca,	   2004).	   It	   can	  induce	   phagocytic	   activity,	   cell	   surface	   antigen	   expression,	   and	   monocyte	  differentiation	  (Abe	  et	  al.,	  1981),	  and	  enhance	  lysosomal	  activity	  and	  interleukin	  1	  production.	  (Bar-­‐Shavit	  et	  al.,	  1981,	  Holick,	  1995).	  1,25(OH)2D3	  inhibits	  interleukin	  2	  production	   in	   activated	  T	   lymphocytes,	   and	  DNA	  synthesis	   and	   immunoglobulin	  (IgM	  and	  IgG)	  production	  in	  activated	  B	  lymphocytes	  (Provvedini	  et	  al.,	  1986).	  	   At	   the	   molecular	   level,	   it	   has	   been	   shown	   that	   1,25(OH)2D3	   can	   inhibit	  adipogenesis	   through	   a	   vitamin	  D	   receptor	   (VDR)-­‐dependent	   inhibition	   of	   CCAAT	  enhancer	   binding	   protein-­‐alpha	   (C/EBPα)	   and	   peroxisome	   proliferator-­‐activated	  receptor-­‐gamma	   (PPARγ)	   expression	   in	   a	   dose-­‐dependent	   and	   time-­‐sensitive	  manner,	   a	   decrease	   in	   PPARγ	   transactivating	   activity,	   and	   a	   stabilization	   of	   the	  inhibitory	   VDR	   protein	   in	   the	   pre-­‐adipocyte.	   Treatment	   of	   the	   3T3-­‐L1	   mouse	  preadipocytes	   cell	   line	   with	   1,25(OH)2D3	   stabilizes	   the	   inhibitory	   VDR	   protein	  levels,	  which	  are	  normally	  increased	  during	  the	  early	  phase	  of	  adipogenesis,	  peaking	  at	   4	   –	   8	   hours	   and	   subsiding	   afterward	   throughout	   the	   rest	   of	   the	   differentiation	  (Kong	  and	  Li,	  2006).	  	  
1.2.4.	  Molecular	  mechanisms	  of	  genomic	  actions	  of	  vitamin	  D	  	  Nuclear	   receptors	   are	   a	   class	   of	   proteins	   found	  within	   cells	   and	   can	   act	   as	  ligand-­‐inducible	   transcription	   factors	   that	   specifically	   regulate	   the	   expression	   of	  target	  genes	  involved	  in	  metabolism,	  development,	  and	  reproduction.	  Their	  primary	  function	   is	   to	   mediate	   the	   transcriptional	   response	   in	   target	   cells	   to	   steroid	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hormones	  or	  other	   lipid	  soluble	  compounds.	  More	   than	  100	  nuclear	  receptors	  are	  known	   to	   exist	   and	   these	   proteins	   comprise	   the	   nuclear	   receptor	   superfamily	  (McKenna	   et	   al.,	   1999).	   	   All	   of	   the	   nuclear	   receptors	   have	   common	   structural	  features	   and	   are	   composed	   of	   several	   independent,	   but	   interacting,	   functional	  modules.	  These	  are	  an	  amino-­‐terminal	  regulatory	  domain	  (A/B	  domain	  containing	  the	   activation	   function	  1	   (AF-­‐1)),	   a	  DNA-­‐binding	  domain	   (DBD;	   region	  C),	   a	   hinge	  region	  (region	  D),	  a	  ligand-­‐binding	  domain	  (LBD;	  region	  E	  containing	  the	  activation	  function	   2	   (AF-­‐2)),	   and	   a	   carboxyl-­‐terminal	   domain	   (region	   F)	   (Giguère,	   1999,	  Olefsky,	  2001).	  The	  vitamin	  D	  receptor	  is	  a	  member	  of	  the	  nuclear	  receptor	  superfamily	  that	  regulates	   the	  expression	  of	  vitamin	  D	  responsive	  gene	  and	  mediates	   the	  biological	  activity	   of	   its	   ligand	   1,25(OH)2D3.	   The	   liganded	   VDR	   can	   form	   a	   VDR-­‐RXR	  heterodimer	  that	   is	  able	  to	  enter	  the	  deep	  groove	  of	  DNA	  and	  recognize	  vitamin	  D	  responsive	  elements	  (VDREs)	  in	  promoter	  region	  of	  vitamin	  D	  target	  genes.	  Binding	  of	  1,25(OH)2D3	   	  to	  the	  VDR	  appears	  to	  cause	  a	  conformational	  change	  at	  the	  COOH	  terminus	  of	  the	  VDR,	  permitting	  	  the	  AF-­‐2	  domain	  (ligand-­‐dependent	  transcriptional	  activation	  domain)	  to	  interact	  with	  other	  transcription	  factors	  including	  coactivator	  proteins	  that	  lead	  to	  activation	  of	  vitamin	  D	  target	  gene	  transcription	  (Masuyama	  et	  al.,	  1997).	  Some	  of	  these	  coactivator	  proteins	  are	  known	  to	  possess	  intrinsic	  histone	  acetylase	  activity	  and	  are	  capable	  of	  chromatin	  modification	  by	  histone	  acetylation	  (Jones	  et	  al.,	  1998,	  Haussler	  et	  al.,	  2008).	  Therefore,	  a	  large	  multiprotein	  coactivator	  complex,	   which	   assembles	   on	   the	   heterodimeric	   VDR-­‐RXR	   complex,	   functions	   to	  remodel	  condensed	  chromatin	  and	  can	   interact	  with	  RNA	  polymerase	  II	   located	  at	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the	  transcriptional	  start	  site	  (Näär	  et	  al.,	  2001).	  These	  interactions	  are	  necessary	  to	  alter	  the	  rate	  of	  gene	  expression	  (Figure	  4).	  	  	  
	  
	   The	   VDR	   interacts	   with	   other	   transcription	   factors,	   such	   as	   transcription	  factor	   IIB	   (TFIIB),	   and	   coactivator	   proteins,	   such	   as	   SRC-­‐1	   and	   TIF-­‐1.	   Nuclear	  receptor	  coactivator	  protein	  (ACTR)	  has	  been	  shown	  to	  enhance	  transcription	  from	  a	   vitamin	  D	   target	   gene	   (Chen	   et	   al.,	   1997,	  McKenna	   and	  O'Malley,	   2002).	   Several	  corepressor	  proteins,	  NCoR,	  SMRT,	  and	  Alien,	  have	  been	  shown	  to	  interact	  with	  the	  
Figure	   4	   Genomic	   actions	   of	   1,25(OH)2D3.	   1,25(OH)2D3	  molecules	   pass	   through	   the	   plasma	  membrane	   with	   the	   help	   of	   vitamin	   D	   binding	   protein	   (DBP).	   	   Ligand	   binding	   to	   the	   VDR	  induces	   a	   conformational	   change	   in	   the	   receptor	   and	   subsequent	   heterodimerization	   with	  RXR	  on	  vitamin	  D	  responsive	  element	  (VDRE).	  Corepressor	  (CoR)	  proteins	  are	  released	  from	  the	  surface	  of	  the	  VDR,	  allowing	  interaction	  with	  coactivator	  (CoA)	  proteins.	  These	  molecules	  modulate	   chromatin	   structure	   and	   allow	   the	   interaction	   of	   the	   receptor	   with	   the	   RNA	  polymerase	  II	  transcriptional	  complex	  (POL	  II),	  thus	  activating	  transcription	  of	  the	  target	  gene	  (	  Seshadri	  et	  al.,	  2011).	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VDR	   and	   block	   VDR-­‐mediated	   transcriptional	   activities	   (Polly	   et	   al.,	   2000).	   The	  hairless	   gene	   product	  HR	   is	   another	   protein	   that	   binds	   directly	   to	   VDR	   and	  VDR-­‐mediated	   transactivation	   is	   strongly	   inhibited	   by	   HR	   in	   a	   manner	   relieved	   by	  1,25(OH)2D3	   (Xie	  et	  al.,	  2006,	  Bikle,	  2009,	  Malloy	  et	  al.,	  2009).	  These	  corepressors	  typically	   bind	   VDR	   in	   the	   absence	   of	   1,25(OH)2D3	   and	   are	   displaced	   when	  1,25(OH)2D3	   binding	   recruits	   the	   coactivators	   to	   the	   VDR.	   Corepressors	   recruit	  histone	   deacetylases	   that	   repress	   transcription	   by	   removing	   acetyl	   groups	   from	  histone	  proteins	  in	  the	  nucleosome	  and	  stabilizing	  chromatin	  (Marks	  et	  al.,	  2001).	  	  Various	  genes	  have	  been	  shown	   to	  be	   responsive	   to	  vitamin	  D	  and	  most	  of	  these	  genes	  play	  a	  direct	  role	  in	  calcium	  endocrinology	  or	  bone	  formation	  including	  osteocalcin,	   osteopontin,	   PTH,	   the	   hydroxylases	   cyp24	   and	   cyp27b1,	   and	   the	  calbindin	   genes.	   Expression	   of	   the	   bone	   protein	   osteocalcin,	  which	   is	   secreted	   by	  osteoblasts	  and	  play	  a	  significant	  role	  in	  maintaining	  bone	  integrity,	  is	  upregulated	  by	  1,25(OH)2D3,	  whereas	   several	   genes	  have	  been	   shown	   to	  be	  downregulated	  by	  1,25(OH)2D3,	   including	   the	   gene	   for	  PTH,	  which	  plays	   a	   critical	   role	   in	   controlling	  the	   levels	   of	   1,25(OH)2D3	   in	   serum.	   Calbindins	   are	   another	   set	   of	   genes	   that	   have	  been	   shown	   to	   be	   regulated	   by	   vitamin	   D.	   Calbindin	   D9K,	   which	   plays	   a	   role	   in	  absorption	   of	   calcium	   from	   the	   mammalian	   gut,	   is	   expressed	   primarily	   in	   upper	  small	   intestine,	   whereas	   the	   calbindin	   D28K,	   which	   may	   be	   involved	   in	   calcium	  reabsorption	  from	  glomerular	  filtrate,	  is	  expressed	  in	  mammalian	  kidney	  and	  other	  tissues	  (Jones	  et	  al.,	  1998).	  1,25(OH)2D3	  stimulates	  the	  differentiation	  of	  many	  cell	  types	  by	  through	  induction	  of	  arrays	  of	  genes	  and	  stimulation	  of	  signal	  transduction	  pathways	   (Marks	   et	   al.,	   2000,	   Samuel	   and	   Sitrin,	   2008).	   Phospholipase	   C	   (PLC)	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activity	  is	  upregulated	  by	  1,25(OH)2D3	  at	  the	  transcriptional	  level	  in	  normal	  human	  keratinocytes	   via	   a	   DR6	   type	   vitamin	   D	   responsive	   element	   (VDRE)	   in	   the	   PLC-­‐1	  	  promoter	  (Xie	  and	  Bikle,	  1997).	  	  The	  CYP24	  hydroxylase,	  an	  immediate	  target	  gene	  of	  VDR,	  is	  one	  of	  the	  most	  highly	  regulated	  genes	   that	  respond	   to	  vitamin	  D.	   In	   the	  presence	  of	   ligand,	   it	   is	  a	  sensitive	  marker	   for	   VDR	   function,	   because	   its	   promoter	   region	   contains	  multiple	  VDREs	  and	  its	  transcription	  is	  very	  responsive	  to	  1,25(OH)2D3	  	  treatment	  (Chen	  and	  DeLuca,	   1995,	   Alimirah	   et	   al.,	   2010).	   1,25(OH)2D3	   is	   thought	   to	   be	   the	   sole	  physiological	   inducer	   of	   24-­‐hydroxylase	   activity	   (Shinki	   et	   al.,	   1992).	   In	   the	  proposed	   studies,	   I	   plan	   to	   use	   cyp24	   gene	   expression	   as	   a	   measure	   of	   VDR	  transcriptional	   activity	   to	   assess	   to	   what	   extent	   histone	   deacetylase	   inhibitors	  (trichostatin	  A	  and	  sulforaphane)	  alter	  cellular	  vitamin	  D	  action.	  	  
1.2.5.	  Molecular	  mechanisms	  of	  non-­‐genomic	  actions	  of	  vitamin	  D	  	  1,25(OH)2D3	   also	   exerts	  biologic	   effects	   that	  do	  not	   appear	   to	   require	   gene	  regulation	   and	   may	   work	   through	   a	   membrane	   receptor	   rather	   than	   its	   nuclear	  hormone	   receptor.	   	   1,25(OH)2D3	   has	   been	   shown	   to	   be	   a	   biological	   regulator	   of	  calcium	  channels	  (Yukihiro	  et	  al.,	  1994)	  by	  acting	  as	  a	  potent	  modulator	  of	  calcium	  channel	   function	   in	   osteosarcoma	   cells	   and	   affecting	   the	   intracellular	   Ca2+-­‐	  dependent	   signaling	   processes	   (Caffrey	   and	   Farach-­‐Carson,	   1989).	   It	   regulates	  chloride	   channel	   activity	   by	   promoting	   the	   rapid	   enhancement	   of	   outwardly	  rectifying	  Cl−	  currents	  in	  a	  concentration-­‐dependent	  manner	  in	  osteoblasts	  (Zanello	  and	  Norman,	  1997),	  and	  plays	  a	  role	  in	  protein	  kinase	  C	  activation	  and	  distribution	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by	  increasing	  the	  breakdown	  of	  membrane	  phosphoinositides,	  raising	  intracellular	  calcium	  concentration,	  and	  translocating	  protein	  kinase	  C	  (PKC)	  from	  the	  cytosolic	  to	   the	   particulate	   fraction	   of	   Caco-­‐2	   cells	   (Bissonnette	   et	   al.,	   1994).	   	   	   These	   rapid	  nongenomic	   effects	  occurring	   in	  minutes	   could	  be	   elicited	  by	   the	   classical	  nuclear	  VDR	  acting	  at	  the	  cytoplasmic	  membrane	  or	  by	  a	  separate	  membrane	  VDR,	  and	  have	  been	  most	  extensively	  studied	   in	  the	   intestine	  (Bikle,	  2009).	  Transcaltachia,	  which	  describes	  the	  rapid	  hormonal	  stimulation	  of	  intestinal	  calcium	  transport,	  occurs	  via	  nongenomic	  mechanisms,	  which	   involve	  a	  plasma	  membrane	  receptor	   (Nemere	  et	  al.,	  1984).	  The	  physiological	  role	  of	  Transcaltachia	  is	  unknown.	  
1.3	  Epigenetic	  modulation	  of	  gene	  expression	  	   Conrad	  Waddington	  originally	  defined	  epigenetics	  as	  ‘‘the	  study	  of	  the	  causal	  interactions	   between	   genes	   and	   their	   products,	   which	   bring	   the	   phenotype	   into	  being”,	  referring	  to	  all	  molecular	  pathways	  modulating	  the	  expression	  of	  a	  genotype	  into	  a	  particular	  phenotype.	  Today,	  epigenetics	  has	  been	  generally	  accepted	  as	  ‘‘the	  study	  of	  changes	   in	  gene	   function	   that	  are	  mitotically	  and/or	  meiotically	  heritable	  and	   that	   do	   not	   entail	   a	   change	   in	   DNA	   sequence,	   including	   histone	   variants,	  posttranslational	   modifications	   of	   amino	   acids	   on	   the	   amino-­‐terminal	   tail	   of	  histones,	  and	  covalent	  modifications	  of	  DNA	  bases.’’	  (Dupont	  et	  al.,	  2009).	  Epigenetic	  modifications	  altered	  by	  external	  or	  internal	  environmental	  factors	  can	  change	  gene	  expression	   and	   maintain	   the	   acquired	   phenotype	   permanently.	   Thus,	   epigenetics	  can	  provide	  a	  new	  model	  for	  the	  search	  for	  etiological	  factors	  of	  many	  diseases,	   in	  particular	   environment-­‐associated	   diseases	   known	   to	   be	   affected	   by	   many	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environmental	  factors	  (Choi	  and	  Friso,	  2010).	  Epigenetic	  modification	  includes	  DNA	  methylation,	  histone	  modifications,	  and	  chromatin	  remodeling.	  
1.3.1	  Histone	  acetylation	  	   Histone	  proteins	  and	  their	  posttranslational	  modifications	  have	  an	  important	  role	   in	   chromatin	   structure,	   nucleosome	   assembly,	   and	   regulation	   of	   gene	  transcription.	   Histone	   acetylation	   is	   one	   of	   the	   most	   extensively	   studied	   histone	  modifications	   associated	  with	   transcriptional	   activation	   (Figure	   5)	   (Dupont	   et	   al.,	  2009).	  	  
	  
	   	  	   A	   nucleosome	   is	   a	   building	   block	   of	   chromatin	   and	   consists	   of	   double-­‐stranded	   DNA	   and	   an	   octamer	   of	   four	   different	   (H2A,	   H2B,	   H3,	   H4)	   histones.	  
Figure	   5	   Regulations	   of	   chromatin	   structure	   and	   transcription	   by	   activities	   of	   HATs	   and	  HDACs.	   The	   amino	   termini	   of	   histones,	   which	   are	   called	   histone	   tails,	   can	   be	   post-­‐translationally	   modified.	   HAT	   acetylates	   lysine	   residues	   (K)	   of	   the	   histones	   and	   HDAC	  removes	   the	   acetyl	   group	   (http://www.biotek.com/resources/articles/cellular-­‐lantha-­‐screen-­‐histone.html).	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Chromatin	  can	  regulate	  transcriptional	  processes	  through	  modifications	  of	  DNA	  and	  the	  histone.	  The	  location	  of	  the	  reversible	  histone	  modifications	  is	  at	  the	  N-­‐terminal	  histone	  tails,	  where	  the	  lysine	  residues	  are	  on	  the	  surface	  of	  the	  nucleosome.	  (Choi	  and	  Friso,	  2010).	  Acetylation	  of	  the	  lysine	  residues	  neutralizes	  the	  positive	  charges	  on	  the	  lysine	  amino	  groups	  and	  decreases	  their	  affinity	  for	  DNA,	  thus	  weakening	  the	  association	  between	  histones	  and	  DNA	  and	  altering	  the	  nucleosomal	  conformation	  (Figure	  6.	   (Hong	  et	  al.,	   1993).	  This	   chromatin	  conformational	   change	  can	   increase	  the	   accessibility	   of	   transcriptional	   regulatory	   proteins	   to	   chromatin	   templates,	  leading	   to	   increased	   transcriptional	   activity	   (Struhl,	   1998).	   Histone	   acetylation	  status	   is	   modulated	   by	   histone	   acetyltransferase	   (HAT)	   and	   histone	   deacetylase	  (HDAC)	  activity	  (Figure	  5,	  (Zhang	  et	  al.,	  2002)).	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
	   	  
Figure	   6	   Acetylation	   and	   deacetylation	   of	   the	   lysine	   residue.	   A	   HAT	   catalyzes	   the	  transfer	  of	  an	  acetyl	  group	  from	  acetyl	  CoA	  to	  the	  amino	  group	  of	  the	  lysine	  residue.	  HAT,	  histone	  acetyltransferase;	  HDAC,	  histone	  deacetylase	  (Yang	  and	  Seto,	  2007).	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1.3.2	  Histone	  deacetylase	  inhibitors	  (HDACIs)	  	  	   Histone	  deacetylases	   (HDACs)	   catalyze	   the	   removal	  of	   acetyl	  groups	  on	   the	  amino-­‐terminal	   lysine	   residues	   of	   core	   nucleosomal	   histones.	   This	   activity	   is	  associated	  generally	  with	  transcriptional	  repression	  (Figure	  5).	  Histone	  deacetylase	  inhibitors	  (HDACIs)	  inhibit	  the	  activity	  of	  HDAC	  and	  induce	  hyperacetylation	  of	  core	  histones,	   thereby	   modulating	   the	   chromatin	   structure	   and	   affecting	   the	   gene	  expression	  (de	  Ruijter	  et	  al.,	  2003)	  	  	   Inhibitors	  of	  HDAC	  activity	  can	   induce	  upregulation	  and	  downregulation	  of	  a	  
small	  subset	  of	  cellular	  genes,	  suggesting	  that	  HDACIs	  act	  selectively	  on	  specific	  genes.	  In	  fact,	  HDACIs	  alter	  the	  transcription	  of	  only	  approximately	  2%	  of	  expressed	  genes	  with	   a	   variable	   transcriptional	   outcome	   (Van	   Lint	   et	   al.,	   1996,	  Marks	   et	   al.,	   2001,	  Moreira	  et	  al.,	  2003).	  Furthermore,	  chromatins	  of	  normal	  and	  transformed	  cells	  are	  differentially	  affected	  by	  histone	  deacetylase	   inhibitors.	  Normal	  cells	  are	  up	   to	   ten	  times	  more	   resistant	   to	   histone	   deacetylase	   inhibitor	   (HDACI)-­‐induced	   cell	   death	  compared	  with	   transformed	  cells	  due	   to	   the	  difference	   in	  chromatin	  conformation	  and	   accessibility	   between	   normal	   and	   transformed	   cells	   (Kim	   et	   al.,	   2003).	   The	  transformed	   cells	   have	   different	   nuclear	   sizes	   and	   cellular	   shapes	   compared	  with	  the	   normal	   cells	   (Zink	   et	   al.,	   2004).	   In	   transformed	   cells,	   acetylation	   of	   K16	   on	  histone	   H4	   (H4-­‐K16Ac)	   is	   markedly	   reduced	   (Fraga	   et	   al.,	   2005),	   and	   levels	   of	  histone	   acetylation	   can	   directly	   impact	   chromatin	   accessibility	   at	   specific	   loci	  (Ehrenhofer-­‐Murray,	   2004).	   Altered	   chromatin	   structure	   may	   increase	   the	  accessibility	   to	   the	   histone	   tails,	   indicating	   that	   the	   structural	   characteristic	   of	  transformed	  cells	  predispose	  them	  to	  HDACI	  sensitivity.	  However,	  the	  mechanisms	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that	   affect	   chromatin	   structure	   and	   the	   molecular	   processes	   underlying	   this	  selectivity	   for	   transformed	   cells	   are	   still	   not	   well	   understood	   (Nalabothula	   and	  Carrier,	  2011).	  	  	   Sodium	   butyrate,	   phenylbutyrate,	   trichostatin	   A	   (TSA),	   suberoylanilide	  hydroxamic	   acid	   (SAHA),	   trapoxin	   (TPX),	   MS-­‐27–275,	   apicidin,	   oxamflatin,	   and	  FR901228	  are	  the	  known	  compounds	  that	  inhibit	  HDAC	  activity	  and	  cause	  a	  variety	  of	   effects,	   including	   cell	   growth	   inhibition,	   cell	   differentiation	   and	   apoptotic	   cell	  death	  (Moreira	  et	  al.,	  2003).	  
1.3.2.1	  Trichostatin	  A	  (TSA)	  
	  
	  	   	  	   	  	  	  	  	   	  	   There	   have	   been	   many	   histone	   deacetylase	   inhibitors	   discovered,	   but	   the	  most	  potent	  is	  trichostatin	  A	  (TSA,	  	  7-­‐[4-­‐(dimethylamino)phenyl]-­‐N-­‐hydroxy-­‐4,6R-­‐dimethyl-­‐7-­‐oxo-­‐2E,4E-­‐heptadienamide,	  Figure	  7).	  TSA	  is	  a	   fermentation	  product	  of	  Streptomyces	  and	  belongs	  to	  the	  hydroxamic	  acid	   family.	  Originally	   it	  was	  used	  as	  an	  anti-­‐fungal	  agent,	  but	   later	   it	  was	   found	   to	  have	  potent	  proliferation-­‐inhibitory	  
Figure	  7	  Trichostatin	  A	  (TSA,	  7-­‐[4-­‐(dimethylamino)phenyl]-­‐N-­‐hydroxy-­‐4,6-­‐dimethyl-­‐7-­‐oxohepta-­‐2,4-­‐dienamide)	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properties	  with	   cancer	   cells.	  TSA	   is	   effective	   at	  nanomolar	   concentrations	   in	  vitro	  (Yoshida	  et	  al.,	  1990,	  de	  Ruijter	  et	  al.,	  2003).	  	  It	  interacts	  reversibly	  with	  the	  HDAC	  catalytic	   site	   to	   prevent	   binding	   of	   the	   substrate	   and	   leads	   to	   histone	   acetylation	  (Finnin	  et	  al.,	  1999).	   	   It	  has	  been	  known	  to	  induce	  cell	  cycle	  arrest,	  differentiation,	  and	   apoptosis.	   (Finnin	   et	   al.,	   1999,	  Marks	   et	   al.,	   2000,	   Tóth	   et	   al.,	   2004).	   Table	   1	  provides	   information	   on	   the	   experimental	   parameters	   tested	   in	   published	   TSA	  studies.	  These	  studies	  show	  that	  TSA	  modified	  histone	  acetylation	  status	  and	  gene	  expression	   levels	   of	   some	   genes	   at	   nano-­‐	   or	   micromolar	   concentrations.	   TSA	   at	  concentration	  of	  1	  μM	  was	  used	  in	  3T3L1	  cells	  in	  my	  study.	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Reference	  Human	   breast	  carcinoma	  cells	   MDA	   468	  and	   435,	  human	  bladder	  carcinoma	  cells	  T24	  
0.1,	   0.3,	  1	  (μM)	   24	  h	   Histone	  hyperacetylation,	   p21,	  Hep27,	   α-­‐Fucosidase,	  Histone	   H2B,	   TRPM-­‐2,	  α-­‐Tubulin,	  Glutaredoxin,	  Metallothionein	   1L,	  Thymidylate	  synthetase,	   TRP,	  Importin	   β,	   APRIL,	   CTP	  synthase	   expression,	  acetylation	   of	   α-­‐tubulin	  in	   T24	   cells	   and	  expression	  of	  a	  core	  set	  of	  genes	  
p21,	  Hep27,	  	  α-­‐Fucosidase,	  	  Histone	  H2B,	  TRPM-­‐2,	  	  α-­‐Tubulin,	  Glutaredoxin,	  Metallothionein	   1L	  were	   up-­‐regulated	  by	   2.8	   -­‐	   48.3	   folds,	  Thymidylate	  synthetase,	   TRP,	  Importin	   β,	   APRIL,	  CTP	   synthase	   were	  down-­‐regulated	   by	  3.7	  –	  7.4	  folds.	  
(Glaser	   et	  al.,	  2003)	  
HeLa-­‐H2A-­‐YFP	  cell	  line	   12.5,	   25,	  50,	   100,	  200	  (ng/ml)	  
2,	   6,	   12,	  24	  h	   Histone	   acetylation	   on	  the	   interphase	  chromatin	  conformation	  
Cell	   density	   was	  reduced	   to	   about	  50%	   (Tóth	  et	  al.,	  2004)	  Human	  prostate	  cancer	  cell	   line	  LNCaP,	   human	  breast	   cancer	  cell	   lines	   T-­‐47D,	  ZR-­‐75-­‐1	  
100,	   200	  (ng/ml)	   24	  h	   Expression	   of	  housekeeping	   genes	  including	   18S	   rRNA,	   β	  actin,	   GAPDH	   and	  ribosomal	   highly-­‐basic	  23-­‐kDa	   protein	   (rb	   23-­‐kDa,	  RPL13A)	  
Either	   up-­‐regulated	  (LNCaP	  and	  ZR-­‐75-­‐1	  at	   100	   ng/ml	   TSA)	  or	   down-­‐regulated	  (prostate	   explants,	  T-­‐47D,	   LNCaP	   and	  ZR-­‐75-­‐1	   at	   200	  ng/ml	  TSA)	  
(Mogal	   and	  Abdulkadir,	  2006)	  
Human	  prostate	   BPH-­‐1	   cells,	  prostate	  cancer	   PC-­‐3	  and	   LNCaP	  cells	  
100	  ng/ml	   48	  h	   P21Cip1/Waf1	   and	   Bax	  protein	   expression,	  HDAC	   activity	   level,	  acetylated	   histone	  levels,	   p21	   expression,	  multi-­‐caspase	  activity	  
Lowered	   HDAC	  activity	  by	  30%	   (Myzak	   et	  al.,	  2006)	  
Human	  prostate	  cancer	   cell	  lines;	   DU145,	  LNCaP,	  PC3	  
50,	   100,	  200,	  300,	  400	  (nM)	  
8	  h	   Expression	   of	   CYP24A1	  mRNA	   CYP24A1	   enzyme	  activity	   was	  increased	  by	  1.6	  –	  4	  fold	  
(Luo	   et	   al.,	  2010)	  
Mouse	   3T3-­‐L1	  cells	   100	  nM	  	   1,	  2,	  4,	  6,	  8	  days	   Expression	   of	  adipogenic	   marker	  genes:	   LIPE,	   AdipoQ,	  and	   aP2,	   expression	   of	  PPARγ	   and	   Fabp4,	   and	  SREBP-­‐1c	  or	  C/EBPβ	  
HDACIs	   block	  adipogenesis.	   (Haberland	  et	   al.,	  2010)	  
Human	   lung	  fibroblasts	  2BS,	   Human	  embryonic	  kidney	  HEK293T	  
1,	  2	  (µM)	   12,	  24 h	   Changes	   of	   HBP1	  acetylation,	   p16INK4A	  expression	   Transcriptional	  activity	   of	   p16INK4A	  promoter	   was	  increased	   to	   about	  10-­‐fold	  	  
(Wang	   et	  al.,	  2012)	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1.3.2.2	  Sulforaphane	  (SFN)	  
	  
	  	  	  
	   Bioactive	   food	   components	   are	  defined	  as	   a	   constituent	   in	   foods	  or	  dietary	  supplements,	  other	  than	  those	  needed	  to	  meet	  basic	  nutritional	  needs	  that	  may	  be	  responsible	   for	   changes	   in	   health	   status.	   Sulforaphane	   	   (1-­‐isothiocyanato-­‐4-­‐(methylfulfinyl)-­‐butane	   or	   SFN,	   Figure	   8)	   is	   a	   bioactive	   food	   component	   found	   in	  cruciferous	  vegetables,	   such	  as	  broccoli,	   cauliflower,	  brussels	  sprouts,	   cabbages	  or	  kale.	  It	  is	  a	  naturally	  occurring	  sulfur-­‐containing	  isothiocyanate	  derivative	  produced	  during	  the	  hydrolysis	  of	  glucosinolates.	  When	  cruciferous	  vegetables	  are	  chopped	  or	  chewed,	  myrosinase	  interacts	  with	  glucosinolates	  and	  releases	  isothiocyanates	  from	  their	  precursors	  (Figure	  9.	  (Zhang,	  2004)).	  
	  
	  	  
Figure	  8	  Sulforaphane	  (SFN,	  1-­‐Isothiocyanato-­‐4-­‐methylsulfinylbutane)	  
Figure 9 Myrosinase-catalyzed conversion of glucosinolate to isothiocyanate 
	  	   24	  
	   Sulforaphane	   has	   multiple	   biological	   effects,	   including	   an	   ability	   to	   affect	  xenobiotic	   metabolism	   by	   inhibiting	   and	   inducing	   various	   biotransformation	  enzymes,	  and	  to	  alter	  gene	  expression	  by	  inducing	  epigenetic	  modifications	  (Mahéo	  et	   al.,	   1997,	   Basten	   et	   al.,	   2002,	   Myzak	   et	   al.,	   2004).	   It	   also	   exhibits	   many	   other	  biological	  activities	  such	  as	  preservation	  of	  normal	  cell	  cycle	  regulation(Chiao	  et	  al.,	  2002),	   inhibition	   of	   proliferation	   	   and	   induction	   of	   apoptosis	   (Singh	   et	   al.,	   2009),	  anti-­‐inflammatory	   activity	   (Heiss	   et	   al.,	   2001),	   antibacterial	   activity	   (Fahey	   et	   al.,	  2002),	   and	   antidiabetic	   activity	   (Song	   et	   al.,	   2009).	   Furthermore,	   sulforaphane	   is	  known	  to	  be	  a	  histone	  deacetylase	  inhibitor,	  which	  induces	  acetylation	  of	  chromatin	  protein	  and	  affects	  the	  expression	  of	  genes	  by	  modulating	  transcriptional	  activation	  of	   the	   genes.	   Myzak	   et	   al.	   reported	   that	   SFN	   acted	   as	   HDACIs	   with	   evidence	   of	  altered	   histone	   acetylation	   status	   and	   increased	   p21Cip1/Waf1	   expression	   in	   human	  embryonic	   kidney	   293	   cells	   and	   HCT116	   colon	   cancer	   cells	   (Myzak	   et	   al.,	   2004).	  	  Table	  2	  provides	   information	  on	   the	  experimental	  parameters	   tested	   in	  published	  SFN	   studies.	   	   	   These	   studies	   show	   that	   SFN	  modified	   histone	   deacetylase	   activity	  level	   or	   histone	   acetylation	   status,	   and	   gene	   expression	   levels	   of	   some	   genes	   at	  various	   micromolar	   concentrations.	   SFN	   at	   concentration	   of	   5	   μM	   was	   used	   in	  3T3L1	  cells	  in	  my	  study.	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Table	  2	  SFN	  study	  experimental	  parameters	  	  	  
	  
Cell	  Type	   SFN	  Dosage	   Exposure	  Time	   Outcome	  Measure	   	  Effect	   	  Reference	  Human	  embryonic	  kidney	   293	  (HEK293)	  cells,	   Human	  HCT116	  colorectal	  cancer	  cells	  
3,	   9,	   15	  (μM)	   47	  h	   HDAC	   activity;	  activity	   of	   a	   β-­‐catenin-­‐responsive	  reporter	  (TOPflash)	  	  	  	  p21Cip1/Waf1	  expression	  
SFN	   alone	  increased	  reporter	   activity	  by	   3.9-­‐fold	   and	  >8-­‐fold	   in	  combination	  with	   TSA	   (100	  ng/ml).	  	  About	   4-­‐fold	  increase	   in	  p21Cip1/Waf1	  expression	  
(Myzak	   et	   al.,	  2004)	  
Human	  prostate	  BPH-­‐1	   cells,	  prostate	  cancer	   PC-­‐3	  and	   LNCaP	  cells	  
3,	   9,	   15	  (µM)	   48	  h	   P21Cip1/Waf1	   and	  Bax	   protein	  expression,	  HDAC	   activity	  level,	   acetylated	  histone	   levels,	  p21	   expression,	  multi-­‐caspase	  activity	  
SFN	   (15	   μM,	   for	  48	   h)	   inhibited	  HDAC	   activity	   by	  40,	   30	   and	   40%,	  p21	   protein	  expression	   was	  increased	  by	  50–100%,	   and	   pro-­‐apoptotic	  protein	  Bax	   was	  increased	   by	  50%	  	  
(Myzak	   et	   al.,	  2006)	  
Human	  colorectal	  cancer	   Caco-­‐2,	   HT-­‐29	   and	  SW480	  cells	  
1,	   10,	   20	  (μM)	   24	  and	  48	  h	   Expression	   of	  HBD-­‐2,	   VDR,	  PPARγ,	   ERK1/2,	  phospho-­‐ERK1/2,	   p38	  MAPK	   and	  phospho-­‐p38	  MAPK	  	  
SFN	   (20	   μm)	  increased	   β-­‐defensin-­‐2	  mRNA	  expression	   up	   to	  5.5-­‐fold	   (HT-­‐29)	  and	   HBD-­‐2	  protein	  expression	   up	   to	  104%	  (Caco-­‐2)	  
(Schwab	   et	   al.,	  2008)	  
Human	  prostate	  cancer	   LNCaP	  and	  C4-­‐2	  cells	  
10,	   20	   or	  40	  (μM)	   24	  h	   Levels	   of	  androgen	  receptor	   (AR)	  protein,	  Ser210/213-­‐phosphorylat-­‐ed	  AR,	   prostate	  specific	   antigen	  (PSA)	   protein	  and	  AR	  mRNA	  
40–80%	  decrease	   in	   AR	  promoter	  activity.	  Phosphorylat-­‐ed	  AR,	   PSA	   protein,	  and	   AR	   mRNA	  levels	  in	  both	  cell	  lines	   were	  decreased	  
(Kim	   and	  Singh,	  2009)	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   Sulforaphane	   can	   readily	   permeate	   the	   enterocytes	   in	   the	   perfused	   human	  jejunal	   segment.	   At	   a	   physiologically	   relevant	   concentration	   11.0	   ±	   2.7	   μM,	   the	  percentage	  of	  absorption	   (±	  S.D.)	   is	  74	  ±	  29%	  (Petri	  et	  al.,	  2003).	  Chewing	  of	   raw	  cruciferous	   vegetables	   may	   increase	   glucosinolate	   contact	   with	   plant	   myrosinase	  and	  increases	  the	  amount	  of	  isothiocyanates	  absorbed,	  and	  the	  myrosinase	  activity	  of	   human	   intestinal	   bacteria	   also	   allows	   for	   some	   formation	   and	   absorption	   of	  isothiocyanates	  (Shapiro	  et	  al.,	  1998).	  It	  has	  been	  estimated	  that	  the	  amount	  of	  SFN	  in	   1	   g	   of	   dry	   broccoli	   florets	   ranges	   from	   507	   to	   684	   μg	   (Campas-­‐Baypoli	   et	   al.,	  2010)	  and	  approximately	  20	  μmol/l	  SFN	  can	  be	  derived	  from	  consumption	  of	  50	  g	  of	  broccoli	   (Chuang	  LT.	   et	   al.,	   2013).	  The	  bioavailability	   study	  showed	   that	  higher	  amounts	  of	  SFN	  were	  found	  in	  the	  blood	  and	  urine	  when	  200	  g	  broccoli	  was	  eaten	  raw	  (bioavailability	  of	  37%)	  versus	  cooked	  (3.4%).	  Absorption	  of	  SFN	  was	  delayed	  when	  cooked	  broccoli	  was	   consumed	   (peak	  plasma	   time	  of	  6	  h)	   compared	   to	   raw	  broccoli	  (1.6	  h).	  Half-­‐lives	  of	  excretion	  were	  comparable,	  2.6	  hours	  and	  2.4	  hours	  on	  average,	  for	  raw	  and	  cooked	  broccoli,	  respectively	  (Vermeulen	  et	  al.,	  2008).	  	  	   Glucosinolates	  are	  hydrolyzed	  by	  myrosinase,	  an	  enzyme	  found	  in	  plants	  and	  bowel	   microflora	   and	   completely	   inactivated	   by	   heat,	   to	   form	   isothiocyanates.	   In	  vivo,	   isothiocyanates	   are	   conjugated	   with	   glutathione	   and	   then	   sequentially	  metabolized	   to	   mercapturic	   acids,	   which	   are	   found	   in	   the	   urine	   (Shapiro	   et	   al.,	  2001).	  These	  isothiocyanate	  metabolites	  are	  highly	  correlated	  with	  dietary	  intake	  of	  cruciferous	  vegetables	  (Seow	  et	  al.,	  1998).	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1.3.3	  Epigenetic	  modulation	  of	  vitamin	  D-­‐mediated	  gene	  expression	  by	  HDACI	  	   Various	  studies	  (Gommersall	  et	  al.,	  2004b,	  Banwell	  et	  al.,	  2006,	  Wang	  et	  al.,	  2008,	   Luo	   et	   al.,	   2010,	   Schwab	   et	   al.,	   2008)	   have	   revealed	   that	   the	   function	   of	  1α,25(OH)2D3	   can	   be	   enhanced	   in	   combination	   with	   HDACIs,	   thereby	  modulating	  the	   expressions	   of	   vitamin	   D-­‐mediated	   genes.	   Table	   3	   shows	   the	   studies	   that	  demonstrated	   the	   modulated	   effects	   of	   vitamin	   D-­‐mediated	   gene	   expression	   by	  HDACIs.	  	   TSA	  activity	  on	  CYP24A1	  expression	  was	  tested	  in	  prostate	  cancer	  cells	  and	  the	   result	   showed	   that	   the	   treatment	   with	   trichostatin	   A	   (TSA)	   enhanced	   the	  expression	  of	  CYP24A1	  in	  LNCaP	  and	  PC3	  cells	  and	  induced	  its	  expression	  in	  a	  dose-­‐dependent	  and	  1,25(OH)2D3-­‐dependent	  manner	  (Luo	  et	  al.,	  2010).	  Furthermore,	  the	  epigenetic	   effect	   of	   HDACI	   activity	   on	   the	   binding	   of	   the	   VDR	   to	   the	   CYP24A1	  promoter	   region	   was	   also	   tested	   in	   PC3	   cells	   treated	   with	   TSA	   and	   a	   significant	  increase	   in	   binding	   of	   VDR	   to	   the	   CYP24A1	   promoter	   with	   TSA	   treatment	   was	  observed	  (Luo	  et	  al.,	  2010).	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Reference	  Prostate	  cancer	  cell	  lines;	  PC-­‐3	  	   15	  nM	  TSA	  	  100	  nM1α,25-­‐(OH)2D3	  	   7	  h	  	   GADD45α	  	   Induction	  of	  gene	  expression	  was	  increased	  by	  4.3-­‐fold	  	   (Gommersall	  et	  al.,	  2004a)	  PZ-­‐HPV-­‐7	  cell	  line	  	   10	  μM	  SAHA	  	  50	  nM	  25-­‐(OH)D3	   24	  h	   1α-­‐OHase	   2-­‐fold	  increase	  in	  1α-­‐OHase	  promoter	  activity	  and	  more	  than	  a	  30-­‐fold	  stimulation	  in	  1α-­‐OHase	  mRNA	  expression	  	  
(Wang	  et	  al.,	  2008)	  
Human	  prostate	  cancer	  cell	  lines;	  DU14,	  LNCaP,	  PC3	  
50,	  100,	  200,	  300,	  and	  400	  nM	  TSA,	  100	  nM	  1α,25(OH)2D3	  	  
8	  h	  for	  TSA	  followed	  by	  24h	  for	  1α,25-­‐(OH)2D3	  	  	  
CYP24A1	  	   CYP24A1	  enzyme	  activity	  was	  increased	  by	  about	  1.6	  –	  4	  fold	  and	  CYP24A1	  mRNA	  expression	  was	  increased	  by	  about	  4	  –	  10	  fold	  
(Luo	  et	  al.,	  2010)	  
Human	  colorectal	  cancer	  Caco-­‐2,	  HT-­‐29	  and	  SW480	  cells	  
10	  -­‐	  20	  μM	  SFN	  	   24	  and	  48	  h	  	   VDR	   Increased	  the	  production	   (Schwab	  et	  al.,	  2008)	  
SCC4,	  MDA-­‐MB231	   100	  nM	  Triciferol	  	   8	  h	   1,25D3-­‐dependent	  gene	  (cdkn1c/kip2,	   alox12,	  and	  pex)	  
Gene	  regulatory	  profile	  is	  distinct	  from	  that	  of	  1,25D	   (Tavera-­‐Mendoza	  et	  al.,	  2008)	  
VDR	  	   Enhanced	  markedly	  VDR	  binding	  to	  the	  cyp24	  promoter	  Cyp24	   Induced	  strong	  expression	  within	  a	  factor	  of	  ≈10	  as	  potent	  as	  1,25D	  p57KIP2(cdkn1c/kip2)	   Markedly	  up-­‐regulated	  col13a1	   Induced	  VDR	  binding	  to	  the	  VDRE	  	  P160	  coactivaor	  AIB1	   Induced	  its	  recruitment	  to	  VDR-­‐bound	  target	  genes	  	   	  	   TSA	  can	  upregulate	  the	  expressions	  of	  target	  genes	  of	  VDR	  and	  combined	  use	  of	   1α,25(OH)2D3	   and	   TSA	   may	   be	   an	   effective	   therapeutic	   for	   some	   cancers	  (Gommersall	   et	   al.,	   2004b).	   Combinations	   of	   1α,25(OH)2D3	   	   compounds	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(1α,25(OH)2D3	  	  or	  its	  analogue	  1α,25-­‐dihydroxy-­‐16,23Z-­‐diene-­‐26,27-­‐hexafluoro-­‐19-­‐nor	  1α,25(OH)2D3	  	  (RO-­‐26-­‐2198),	  100	  nmol/L)	  with	  TSA	  (15	  nmol/L)	  restored	  VDR	  antiproliferative	   signaling	   in	   breast	   cancer	   cell	   lines	   T-­‐47D,	   ZR-­‐75-­‐1,	   MCF-­‐7,	   and	  MDA-­‐MB-­‐23.	   Cotreatment	   with	   RO-­‐26-­‐2198	   and	   TSA	   showed	   significant	  enhancement	  of	  mRNA	  accumulation	  of	  target	  genes	  GADD45α,	  VDUP-­‐1	  and	  CYP24	  in	  MDA-­‐MB-­‐231	  cells	  notably	  at	  12	  hours	  (Banwell	  et	  al.,	  2006).	  	   Triciferol,	   a	   hybrid	   molecule	   in	   which	   the	   1α,25(OH)2D3	   side	   chain	   is	  replaced	  with	  TSA,	  binds	  directly	  to	  the	  VDR	  ligand	  binding	  domain	  and	  functions	  as	  an	   agonist	  with	   1α,25(OH)2D3-­‐like	   potency	   on	   several	   1α,25(OH)2D3	   target	   genes.	  Triciferol	  (100	  nM)	  induced	  strong	  cyp24	  expression	  and	  exhibited	  more	  efficacious	  antiproliferative	   and	   cytotoxic	   activities	   than	   1α,25(OH)2D3	   (100	   nM)	   alone	   in	  human	  squamous	  carcinoma	  cells	  SCC4	  and	  SCC25,	  and	  human	  breast	  cancer	  cells	  MCF-­‐7	  and	  MDA-­‐MB231	  (Tavera-­‐Mendoza	  et	  al.,	  2008).	  	   Suberoylanilide	   hydroxamic	   acid	   (SAHA)	   increases	   the	   expression	   of	   genes	  that	   modulate	   cell	   cycle	   progression,	   tumor	   suppression,	   differentiation	   and	  apoptosis	   in	   PZ-­‐HPV-­‐7	   prostate	   cells.	   SAHA	  upregulates	   the	   expression	   of	   the	   1α-­‐hydroxylase	  gene	  (CYP27B1)	  that	  controls	  the	  synthesis	  of	  1α,25(OH)2D3	  regulating	  prostate	  growth	  and	  differentiation	  in	  an	  autocrine/paracrine	  fashion	  (Wang	  et	  al.,	  2008).	  	  	   Schwab	   et	   al.	   demonstrated	   that	   sulforaphane	   (SFN,	   10–20	   μmol/L),	   a	  dietary	  HDACI,	   increased	  the	  production	  of	  VDR	  protein	   in	  HT-­‐29	  and	  Caco-­‐2	  cells	  (Schwab	  et	  al.,	  2008)	  after	  24-­‐hour	  treatment.	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1.4	  Vitamin	  D	  and	  adipogenesis	  in	  3T3L1	  Cells	  	   Adipocyte	  differentiation,	  adipogenesis,	   is	  the	  process	  of	  development	  of	  fat	  cells	  from	  preadipocytes,	  and	  has	  been	  one	  of	  the	  most	  intensely	  studied	  models	  of	  cellular	   differentiation.	   To	   investigate	   the	   regulatory	   mechanism	   of	   adipocyte	  differentiation,	   many	   studies	   have	   utilized	   the	   well-­‐established	   mouse	   3T3-­‐L1	  preadipocyte	   experimental	   systems	   as	   a	   cell	   culture	   model	   (Ishida	   et	   al.,	   1988,	  Lagace	   and	  Nachtigal,	   2004,	  Kong	   and	  Li,	   2006).	   The	  3T3-­‐L1	   cells	   are	   fibroblastic	  cells	  already	  determined	  to	  the	  adipocyte	  lineage	  and	  originally	  derived	  from	  mouse	  embryos.	  Fully	  differentiated	  3T3-­‐L1	  adipocytes	  possess	  most	  of	  the	  morphological,	  biochemical,	  and	  hormonal	  response	  characteristics	  of	  adipocyte	  (Gregoire,	  2001).	  	  	   Peroxisome	   proliferator-­‐activated	   receptor-­‐gamma	   (PPARγ)	   and	   CCAAT	  enhancer	  binding	  protein-­‐alpha	  (C/EBPα)	  are	  essential	  in	  adipocyte	  differentiation.	  PPAR	   family	   and	   the	   CCAAT/enhancer-­‐binding	   proteins	   are	   important	  transcriptional	   factors	   involved	   in	   the	   regulation	   of	   differentiation.	   PPARs	   are	  members	  of	  the	  nuclear-­‐receptor	  superfamily	  and	  nuclear	  transcription	  factors,	  and	  form	   heterodimers	  with	   RXRs	   prior	   to	   binding	   of	   DNA	   in	   the	   promoter	   of	   PPAR-­‐responsive	   genes	   (Chu	   et	   al.,	   1995).	   Permanent	   exit	   from	   the	   cell	   cycle	   with	   the	  coexpression	   of	   PPARγ	   and	   C/EBPα	   establishes	   the	   irreversible	   commitment	   to	  adipocyte	   differentiation	   (Shao	   and	   Lazar,	   1997).	   C/EBPα	   terminates	   the	   mitotic	  clonal	  expansion	  preceding	  entry	   into	   the	   terminally	  differentiated	  state	   (Umek	  et	  al.,	   1991)	   and	   activates	   several	   adipogenic	   genes	   that	   create	   and	   maintain	   the	  adipocyte	   phenotype	   by	   autoactivating	   transcription	   of	   its	   own	   gene	   (Lin	   et	   al.,	  1993).	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   1α,25(OH)2D3	  inhibits	  differentiation	  of	  preadipocyte	  to	  adipocyte	  (Ishida	  et	  al.,	   1988)	   and	   reduces	   triacylglycerol	   accumulation	   by	   50%	   of	   that	   of	   fully	  differentiated	   control	   cells	   through	   a	   vitamin	   D	   receptor	   (VDR)-­‐dependent	  inhibition	  of	  C/EBPα	  and	  PPARγ	  expression	  (Kong	  and	  Li,	  2006,	  Wood,	  2008).	  Kong	  et	  al.	  demonstrated	  the	  molecular	  mechanism	  whereby	  1α,25(OH)2D3	  inhibited	  3T3-­‐L1	   	   cell	   adipogenesis	   by	   inhibiting	   only	   the	   early	   events	   of	   adipogenesis	   in	  which	  1α,25(OH)2D3	  could	  effectively	   inhibit	  3T3-­‐L1	  cell	  adipogenesis	  within	   the	   first	  48	  hours	  after	   the	  differentiation	  program	  was	   initiated	   in	  a	  dose-­‐dependent	  manner	  (from	  10−11	  to	  10−7	  M).	  The	  blockade	  of	  3T3-­‐L1	  cell	  differentiation	  by	  1α,25(OH)2D3	  involves	  direct	   suppression	  of	  C/EBPα	  and	  PPARγ	  upregulation,	   antagonization	  of	  PPARγ	  activity,	  and	  stabilization	  of	  the	  inhibitory	  VDR	  protein	  (Kong	  and	  Li,	  2006).	  	  	   Vitamin	   D	   receptor	   (VDR)	   mediates	   1α,25(OH)2D3-­‐mediated	   inhibition	   of	  adipogenesis	  in	  3T3-­‐L1	  cells.	  The	  study	  by	  Kong	  et	  al.	  demonstrated	  that	  the	  level	  of	  VDR	  protein	  was	   increased	  during	   this	  early	  phase	  of	  adipogenesis,	  peaked	  at	  4-­‐8	  hours	   after	   the	   cells	   were	   switched	   to	   differentiation	   media	   (hormonal	   cocktail	  containing	  insulin,	  dexamethasone,	  and	  isobutyl	  methylxanthine)	  containing	  10−8	  M	  1α,25(OH)2D3,	  and	  subsided	  afterward	  along	  the	  progression	  of	   the	  differentiation	  so	  that	  the	  VDR	  protein	  became	  barely	  detectable	  in	  mature	  adipocytes	  at	  day	  8.	  The	  study	  also	  showed	  that	  overexpression	  of	  VDR	  in	  3T3-­‐L1	  cells	  blocked	  adipogenesis.	  These	   results	   indicates	   that	  1α,25(OH)2D3	   	   treatment	   increased	   and	   stabilized	   the	  VDR	  levels	  and	  confirms	  that	  VDR	  is	  inhibitory	  	  on	  3T3-­‐L1	  cell	  	  adipogenesis	  (Kong	  and	   Li,	   2006).	   Given	   that	   VDR	   and	   PPARγ	   share	   the	   same	   heterodimeric	   partner	  RXR,	   Kong	   et	   al.	   suggested	   that	   VDR	   directly	   suppress	   the	   transacting	   activity	   of	  
	  	   32	  
PPARγ	   by	   sequestering	   the	   limited	   amount	   of	   RXR	   in	   3T3-­‐L1	   cells.	   (Kong	   and	   Li,	  2006).	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CHAPTER	  2	  
PURPOSE	  OF	  THE	  STUDY	  
	  	   Although	   some	   studies	   have	   examined	   the	   effects	   of	   TSA	   on	   1,25-­‐dihydroxyvitamin	   D	   mediated	   gene	   expression	   in	   various	   cell	   types	   including	  human	   prostate	   cancer	   cells	   (Luo	   et	   al.,	   2010),	   human	   lung	   fibroblasts,	   human	  embryonic	   kidney	   cells	   (Wang	   et	   al.,	   2008),	   and	   human	   colorectal	   cancer	   cells	  (Schwab	  et	  al.,	  2008),	  to	  my	  knowledge,	  no	  studies	  have	  investigated	  the	  role	  of	  TSA	  in	  murine	  3T3-­‐L1	  in	  preadipocytes	  or	  other	  fat	  cell	  lines.	  	  In	  addition,	  the	  ability	  of	  the	   dietary	   histone	   deacetylase	   inhibitor	   SFN	   to	   alter	   VD/VDR–mediated	   gene	  expression	  has	  not	  been	  explored	  in	  any	  cell	  types.	  	  	  	  	   The	  long-­‐term	  objective	  of	  this	  line	  of	  research	  is	  to	  determine	  to	  what	  extent	  bioactive	  food	  components	  can	  be	  used	  to	  promote	  health.	  The	  objective	  of	  this	  study	  is	   to	   determine	   whether	   epigenetic	   modification	   can	   increase	   vitamin	   D-­‐induced	  gene	   expression	   in	   adipocytes.	   This	   hypothesis	   will	   be	   tested	   by	   successfully	  completing	  the	  following	  Specific	  Aim:	  
Specific	   Aim:	   	   Enhancement	   of	   vitamin	   D	   cellular	   action	   by	   epigenetic	  
modification	  	   Changes	  in	  gene	  expression	  can	  drive	  changes	  in	  cellular	  function.	  Recently,	  there	  has	  been	   increased	  appreciation	  of	   the	  role	  of	  epigenetic	  modification	   in	  the	  control	  of	  gene	  expression.	  Moreover,	  some	  bioactive	  food	  components,	  such	  as	  SFN,	  have	  been	  shown	  to	  cause	  epigenetic	  changes	   in	  nuclear	  chromatin	  due	  to	  histone	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deacetylase	   inhibitor	   activity.	  The	  working	  hypothesis	   tested	   in	   this	   specific	   aim	   is	  that	   treatment	   of	   3T3-­‐L1	   mouse	   preadipocytes	   with	   the	   histone	   deacetylase	  inhibitors	  (tricostatin	  A	  or	  sulforaphane)	  will	  increase	  1,25(OH)2	  vitamin	  D-­‐induced	  gene	   expression,	   as	   evidenced	   by	   an	   increase	   in	   CYP24	   mRNA	   levels	   following	  1,25(OH)2	  vitamin	  D	  and	  HDACI	  treatment	  compared	  to	  1,25(OH)2	  vitamin	  D	  alone.	  This	  hypothesis	  is	  based	  on	  strong	  support	  in	  the	  published	  literature	  showing	  that	  the	   expression	   of	   certain	   genes	   are	   increased	   following	   treatment	   with	   histone	  deacetylase	   inhibitors,	   and	   a	   specific	   report	   that	   vitamin	   D-­‐induced	   CYP24	   gene	  expression	   in	  human	  squamous	  carcinoma	  cell	   lines	  and	  human	  breast	  cancer	  cell	  lines	   are	   increased	   by	   treatment	   with	   triciferol,	   a	   hybrid	   1,25(OH)2	   vitamin	   D	  molecule	  with	  a	  modified	  side	  chain	  containing	  tricostatin	  A	  (Tavera-­‐Mendoza	  et	  al.,	  2008).	   	   To	   our	   knowledge,	   modulation	   of	   vitamin	   D-­‐induced	   gene	   expression	   by	  sulforaphane,	   a	   natural	   histone	   deacetylase	   compound	   found	   in	   cruciferous	  vegetables	   such	   as	   broccoli	   and	   cabbage,	   has	   not	   been	   investigated,	   nor	   has	   the	  effects	  of	  any	  HDACIs	  in	  preadipocytes.	  	  	  The	  rationale	  for	  performing	  this	  research	  is	  that	  since	  1,25(OH)2	  vitamin	  D	  has	   been	   shown	   to	   influence	   gene	   expression	   and	   adipogenesis	   in	   3T3-­‐L1	  preadipocytes	   and	   other	   adipocyte	   cell	   lines,	   the	   findings	   of	   this	   research	  will	   be	  significant	   in	  advancing	  our	  understanding	  of	  how	  altered	   intake	  of	  bioactive	   food	  components	  that	  cause	  specific	  epigenetic	  changes	  in	  cells	  may	  modulate	  the	  action	  of	   the	   vitamin	   D	   hormone	   in	   adipose	   tissue.	   These	   findings	   could	   have	   future	  implications	   in	   the	   design	   of	   vitamin	   D	   intervention	   studies	   to	   influence	   adipose	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metabolism	  and	  help	  combat	  obesity,	  or	  other	  diseases	  in	  which	  vitamin	  D	  may	  be	  involved.	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CHAPTER	  3	  
	  
EXPERIMENTAL	  DESIGN	  AND	  METHODS	  
3.1.	  Experimental	  design	  	   My	  experiment	  investigated	  the	  effect	  of	  two	  histone	  deacetylase	  inhibitors,	  TSA	   and	   SFN,	   on	   24-­‐hydroxylase	   CYP24	   gene	   expression	   levels.	   	   The	   3T3-­‐L1	  preadipocytes	   cell	   culture	   system	   was	   used	   for	   the	   study	   due	   to	   their	   well-­‐documented	   response	   to	   vitamin	   D	   (Sato	   and	   Hiragun,	   1988,	   Kamei	   et	   al.,	   1993,	  Kong	  and	  Li,	  2006).	  I	  measured	  CYP24	  expression	  levels	  by	  PCR-­‐based	  quantitation	  of	   CYP24	  mRNA	   following	   incubation	  of	   cells	  with	  1,25(OH)2	   vitamin	  D	   alone	   and	  1,25(OH)2	   vitamin	   D	   in	   combination	   with	   either	   1µM	   TSA	   or	   5µM	   SFN.	   CYP	   24	  induction	  is	  a	  well-­‐known	  measure	  of	  1,25(OH)2	  vitamin	  D	  responsiveness	   in	  cells.	  In	   order	   to	   confirm	   the	   cells’	   dose-­‐dependent	   responses	   to	   1,25(OH)2	   vitamin	   D,	  three	   different	   1,25(OH)2	   vitamin	   D	   concentrations	   of	   0,	   1,	   and	   10	   nmol/L	   were	  used.	  The	  incubation	  time	  of	  24	  hours	  was	  kept	  as	  a	  constant.	  Concentrations	  of	  TSA	  and	   SFN	   and	   incubation	   period	   were	   set	   in	   accordance	   with	   literature	   values	  (Schwab	  et	  al.,	  2008,	  Wang	  et	  al.,	  2012).	  	  
3.2.	  Cell	  culture	  and	  treatments	  
	   Mouse	   3T3-­‐L1	   preadipocytes	   cells	   were	   grown	   in	   6-­‐well	   culture	   plates	   to	  100%	   confluence	   in	   growth	  media	   (89%	  DMEM,	   10%	   calf	   serum,	   1%	   pen-­‐strep).	  The	  media	  was	   changed	  with	   fresh	   growth	  media	   every	   48	   hours.	   At	   confluence,	  cells	  were	   treated	  with	   3	   different	   concentrations	   of	   hormonal	   form	  of	   vitamin	  D	  (1,25-­‐dihydroxycholecalciferol	   0	   nM,	   1	   nM,	   or	   10	   nM)	   alone	   the	   3	   different	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concentrations	   of	   1,25(OH)2	   vitamin	   D	   	   in	   combination	   with	   either	   1μM	   TSA	  	  (Trichostatin	   A,	   Sigma-­‐Aldrich)	   or	   5μM	   SFN	   (Sulforaphane,	   Sigma-­‐Aldrich)	   for	   24	  hours.	   An	   experiment	   consisted	   of	   6	   different	   treatment	   combinations	   that	   were	  performed	   in	   three	   6-­‐well	   plates,	   and	   so	   there	   were	   2	   replicate	   wells	   for	   each	  treatment	   combination	   including	   vehicles	   (no	   vitamin	   D	   treatment	   (control);	   2	  different	  concentrations	  of	  1,25(OH)2	  vitamin	  D;	  1	  and	  10	  nmol/L	  with	  either	  1μM	  TSA	   or	   5μM	   SFN).	   The	   experiment	   was	   repeated	   7	   times	   (n	   =	   7).	   In	   additional	  experiments,	  1,25(OH)2	  vitamin	  D	  dose-­‐response	  experiment	  at	  0,	  1,	  2,	  5	  and	  10	  nM	  were	  also	  conducted	  in	  the	  presence	  and	  absence	  of	   	  5μM	  SFN.	  These	  experiments	  were	  repeated	  3	  times	  (n	  =	  3).	  
3.3.	  Gene	  Expression	  Analysis	  
3.3.1.	  RNA	  isolation	  	  	   After	  24	  hours	  treatment	  incubation,	  the	  media	  was	  discarded	  and	  cells	  were	  harvested	   to	  assess	  24-­‐hydroxylase	  mRNA	  expression.	  Cells	  were	  scraped	   in	  1	  mL	  Trizol	  reagent	  (Invitrogen)	  and	  RNA	  was	  isolated	  from	  the	  treated	  cells	  according	  to	  the	  manufacturer’s	  protocol.	  In	  brief,	  after	  collecting	  Trizol-­‐treated	  cells	  in	  the	  tube,	  200μL	  chloroform	  was	  used	  for	  phase-­‐separation.	  	  To	  get	  the	  total	  RNA	  pellet,	  RNA	  obtained	  from	  the	  upper	  aqueous	  phase	  layer	  was	  precipitated	  in	  100%	  isopropanol	  (1:1),	   centrifuged	   to	   obtain	   an	   RNA	   pellet,	   and	   then	   washed	   with	   75%	   ethanol	  followed	  by	  centrifugation.	  	  After	  discarding	  the	  supernatant,	  the	  washed	  RNA	  pellet	  was	  resuspended	  in	  DEPC-­‐treated	  water	  (20μl)	  and	  then	  heated	  to	  55oC	  for	  10	  min.	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3.3.2	  RNA	  Quantification	  	   2μl	  of	   the	  RNA	  sample	   in	  DEPC-­‐treated	  water	  was	  diluted	   (1:500)	   in	  998μl	  DEPC-­‐treated	  water	  and	  read	  at	  OD	  of	  260nm	  on	  a	  spectrophotometer	  to	  determine	  RNA	  concentration.	  	  
3.3.3	  Reverse	  transcriptase	  PCR	  (RT-­‐PCR)	  	   First-­‐strand	   cDNA	   was	   synthesized	   from	   isolated	   RNA	   by	   reverse	  transcriptase	   with	   SuperScript	   III	   First-­‐Strand	   Synthesis	   System	   for	   RT-­‐PCR	   kit	  (Invitrogen)	  and	  then	  followed	  by	  PCR	  amplification	  to	  obtain	  the	  specific	  mRNA	  of	  interest.	  cDNAs	  were	  synthesized	  from	  RNA	  in	  a	  final	  volume	  of	  20μl	  using	  2	  μg	  of	  total	  RNA	  as	   input.	   ,	  PCR	  reactions	  were	  performed	  with	  1μl	  of	  cDNA	  per	  reaction	  according	   to	   the	   protocol	   provided	   by	   manufacturer.	   Semiquantitative	   RT-­‐PCR	  method	   was	   used	   to	   assess	   relative	   24-­‐hydroxylase	   (CYP24)	   and	   GAPDH	   gene	  expression.	  The	  sequences	  for	  24-­‐hydroxylase	  and	  GAPDH	  primers	  used	  for	  PCR	  are	  as	  follows	  (Shao	  et	  al.,	  2001).	  	  	  
Gene	   Primer	  Sequence	  Cyp24	   Forward	  5’-­‐CTCATGCTAAATACCCAGGTG-­‐3’	  Reverse	  5’-­‐TCGCTGGCAAAACGCGATGGG-­‐3’	  GAPDH	   Forward	  5’-­‐CCATGGAGAAGGCTGGGG-­‐3’	  Reverse	  5’-­‐CAAAGTTGTCATGGATGACC-­‐3’	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   PCR	   was	   performed	   for	   30	   cycles,	   which	   falls	   within	   the	   linear	   range	   of	  amplification	  for	  both	  24-­‐hydroxylase	  and	  GAPDH.	  	  The	  annealing	  temperature	  that	  was	  used	  for	  PCR	  for	  both	  genes	  is	  55oC.	  	  
3.3.4	  Agarose	  Gel	  Electrophoresis	  	   5	  μl	  of	  loading	  dye	  was	  added	  to	  each	  25ul	  of	  PCR	  product.	  Then,	  6	  μl	  of	  the	  PCR	  sample	  of	  CYP24	  mRNA,	  a	  gene	  of	  interest,	  and	  GAPDH	  mRNA,	  a	  housekeeping	  gene,	  were	  loaded	  into	  wells	  on	  a	  2.5%	  agarose	  gel	  made	  of	  Tris	  acetate-­‐EDTA	  (TAE)	  buffer	  and	  containing	  ethidium	  bromide.	  The	  bands	  obtained	  after	  electrophoresis	  were	  visualized	  under	  UV	  light	  and	  a	  digital	  picture	  of	  the	  gel	  with	  the	  PCR	  product	  bands	   was	   obtained.	   DNA	   band	   intensity	   was	   quantified	   using	   Image	   J	   software	  (NIH)	   and	   relative	   band	   intensity	   of	   24-­‐hydroxylase	   was	   calculated	   against	   the	  respective	  samples	  GAPDH	  housekeeping	  gene.	  The	  fold-­‐change	  in	  expression	  of	  the	  cyp24	  mRNA	  compared	  to	  control	  (no	  treatment	  with	  either	  1,25(OH)2	  vitamin	  D	  or	  HDACI)	  was	  calculated.	  
3.4	  Statistical	  Analysis	  	   Relative	   mRNA	   expression	   was	   analyzed	   in	   Prism	   version	   5.0	   (GraphPad	  Software)	  and,	  when	  appropriate,	  the	  difference	  between	  treatment	  groups	  for	  24-­‐hydroxylase	  mRNA	  expression	  was	   assessed	  by	  post-­‐hoc	   comparison	  of	   treatment	  means.	   Main	   effects	   of	   treatments	   on	   24-­‐hydroxylase	   mRNA	   expressions	   was	  analyzed	   using	   two-­‐way	   ANOVA	   to	   test	   the	   effects	   of	   1,25(OH)2	   	   vitamin	   D	   and	  HDACI	  (TSA	  or	  SFN),	  and	  interaction	  at	  P	  <	  0.05.	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CHAPTER	  4	  
RESULTS	  	  
CYP24	  mRNA	  Expression	  is	  Dependent	  on	  1,25(OH)2	  Vitamin	  D	  Dose	  in	  3T3-­‐L1	  
Mouse	  Preadipocytes	  	   In	  the	  absence	  of	  1,25(OH)2	  vitamin	  D	  there	  was	  no	  evidence	  of	  CYP24	  mRNA	  by	   PCR	   for	   30	   cycles	   (representative	   PCR	   bands	   shown	   in	   Figure	   10);	   however,	  there	   was	   an	   evident	   induction	   of	   CYP24	   mRNA	   expression	   at	   1	   nM	   and	   10	   nM	  1,25(OH)2	   vitamin	   D.	   The	   response	   of	   CYP24	  mRNA	   level	   to	   1,25(OH)2	   vitamin	   D	  treatment	  	  was	  	  dependent	  on	  the	  dose	  (0,	  1,	  2,	  5	  and	  10	  nM	  for	  24h)	  of	  1,25(OH)2	  vitamin	  D	  administered	  (Figure	  11),	  which	  increase	  by	  6.3-­‐fold	  at	  10	  nM	  1,25(OH)2	  vitamin	   D,	   the	   highest	   vitamin	   D	   dose	   investigated	   compared	   to	   1	   nM	   1,25(OH)2	  vitamin	   D,	   the	   lowest	   dose	   to	   evoke	   an	   apparent	   increase	   in	   CYP24	   expression	  (Figure	  10).	  However,	   the	  greatest	  relative	  response	  of	  CYP24	  mRNA	  to	  vitamin	  D	  was	   apparent	   at	   the	   lower	   doses	   between	   1	   and	   2	   nM	   1,25(OH)2	   vitamin	   D,	  suggesting	  an	  approaching	  saturation	  of	  the	  CYP24	  response.	  	  	   1,25	  Vitamin	  D	  (nM)	   0	   1	   10	   0	   1	   10	   0	   1	   10	  SFN	  5uM	   -­‐	   -­‐	   -­‐	   +	   +	   +	   -­‐	   -­‐	   -­‐	  TSA	  1uM 	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   -­‐	   +	   +	   +	  	  
	  	  
Figure	  10.	  	  Relative	  CYP	  24	  mRNA	  amounts	  measured	  by	  semiquantitative	  reverse	  
transcription–PCR	  in	  3T3L1	  preadipocytes.	  CYP	  24	  mRNA	  expressions	  at	  3	  different	  1,25(OH)2	  vitamin	  D	  (nM)	  concentrations	  in	  combination	  with	  either	  1μM	  TSA	  	  (Trichostatin	  A)	  or	  5μM	  SFN	  (Sulforaphane)	  in	  3T3-­‐L1	  preadipocytes.	  	  
	  	  24-­‐hydroxylase	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Figure	  11.	  	  Dose-­‐dependent	  effect	  of	  1,25(OH)2	  vitamin	  D	  on	  CYP	  24	  mRNA	  expression	  in	  3T3-­‐
L1	  preadipocytes.	  With	   increasing	  doses	  of	  1,25(OH)2	  vitamin,	  CYP24	  mRNA	  expression	   increased	  (p	  <	  0.05).	  The	  sharpest	  increase	  in	  CYP24	  mRNA	  appeared	  to	  occur	  at	  the	  lower	  doses	  with	  tapering	  of	   response	   at	   the	   higher	   vitamin	   D	   treatment	   levels.	   	   Results	   indicate	   mean	   ±	   SEM,	   n	   =	   3	  independent	  experiments.	  	  
TSA	   Histone	   Deacetylase	   Inhibitor	   Treatment	   Increases	   Vitamin	   D-­‐induced	  
CYP24	  mRNA	  Expression	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Figure	   12.	   CYP	   24	  mRNA	   expressions	   at	   3	   different	   1,25(OH)2	   vitamin	   D	   concentrations	   in	  
combination	   with	   either	   1μM	   TSA	   	   (Trichostatin	   A)	   or	   5μM	   SFN	   (Sulforaphane)	   in	   3T3-­‐L1	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mRNA	  expression	  in	  the	  presence	  of	  1,25(OH)2vitamin	  D.	  Note	  also	  that	  TSA	  alone	  had	  no	  effect	  on	  CYP24	  mRNA.	  	  Cells	  treated	  with	  TSA	  in	  7	  independent	  experiments	  (Figure	  12)	  had	  higher	  mean	  vitamin	  D-­‐induced	  CYP24	  mRNA	  expression,	   by	  3.8-­‐fold	   (p	  <	  0.05)	   at	   a	   low	  (1nM)	   1,25(OH)2	   vitamin	   D	   dose	   and	   by	   2.4-­‐fold	   (p	   <	   0.05)	   at	   a	   high	   (10	   nM)	  1,25(OH)2	  vitamin	  D	  dose.	  	  
SFN	  Increases	  Vitamin	  D-­‐induced	  CYP24	  mRNA	  Expression	  	   To	  test	  whether	  the	  bioactive	  food	  component	  SFN,	  which	  has	  been	  shown	  to	  have	  HDACI	  activity,	  could	  also	  influence	  vitamin	  D-­‐induced	  CYP24	  gene	  expression	  in	   3T3-­‐L1	   preadipocytes,	   cells	   were	   treated	   with	   3	   different	   concentrations	   of	  1,25(OH)2	  vitamin	  D	  	  (0,1	  and	  10	  nM	  for	  24h)	  with	  or	  without	  5μM	  SFN,	  followed	  by	  measurement	   of	   	   vitamin	   D-­‐induced	   CYP24	   mRNA	   expression.	   The	   apparently	  denser	  PCR	  bands,	  shown	  in	  the	  middle	  set	  of	  bands	  in	  Figure	  10,	  following	  SFN	  and	  1,25(OH)2	   vitamin	   D	   treatment	   compared	   to	   1,25(OH)2vitamin	   D	   treatment	   alone	  (far	   left	   set	   of	   bands	   in	   the	   figure)	   suggest	   an	   apparent	   up	   regulation	   of	   CYP24	  mRNA	  due	  to	  SFN	  treatment.	  This	  notion	  would	  be	  supported	  by	  the	  data,	  shown	  in	  Figure	   13,	   in	  which	   a	   vitamin	  D-­‐induced	   dose-­‐response	   of	   CYP24	   expression	  was	  compared	   with	   and	   without	   concomitant	   SFN	   treatment.	   Over	   3	   independent	  experiments,	   cells	   treated	   with	   5μM	   SFN	   had	   increased	   mean	   vitamin	   D-­‐induced	  CYP24	  mRNA,	  by	  3.6-­‐fold	  at	  1nM	  1,25(OH)2	  vitamin	  D,	  6%	  at	  2	  nM,	  74%	  at	  5	  nM,	  and	  45%	   at	   10	   nM	   1,25(OH)2	   vitamin	   D.	   	   However,	   the	  main	   effect	   of	   SFN	   on	   CYP24	  mRNA	   was	   not	   statistically	   significant	   by	   ANOVA	   (P	   =	   0.0876).	   The	   main	   effect	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difference	   in	  CYP24	  mRNA	  between	  treatments	  without	  and	  with	  SFN	  was	  2842	  ±	  2908.	   The	   reason	   for	   the	   apparent	   lack	   of	   response	   to	   SFN	   at	   2	   nM	   1,25(OH)2	  vitamin	  D	  in	  these	  experiments	  is	  unknown,	  but	  may	  reflect	  a	  possible	  experimental	  anomaly	  given	  the	  apparent	  effect	  of	  SFN	  at	   the	  both	   	   lower	  and	  higher	  vitamin	  D	  doses. 
	  
Figure	  13.	  Dose-­‐dependent	  effect	  of	  1,25(OH)2	  vitamin	  D	  in	  combination	  with	  SFN	  on	  CYP	  24	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mRNA	   expression.	   Based	   on	   our	   findings,	   it	   appears	   that	   the	   ability	   of	   SFN	   to	  increase	  CYP24	  induction	  by	  1,25(OH)2	  vitamin	  D	  is	  not	  as	  effective	  as	  TSA.	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CHAPTER	  5	  
DISCUSSION	  	  	   1,25(OH)2	   vitamin	   D	   	   has	   been	   known	   for	   a	   long	   time	   to	   inhibit	   the	  differentiation	   of	   preadipocytes	   to	   adipocytes	   (Ishida	   et	   al.,	   1988)	   in	   a	   vitamin	   D	  receptor	   (VDR)-­‐dependent	   manner.	   In	   this	   study,	   we	   used	   the	   mouse	   3T3-­‐L1	  preadipocyte	  experimental	  system,	  which	  is	  a	  well-­‐established	  cell	  culture	  model	  to	  study	  the	  mechanism	  of	  adipocyte	  differentiation,	  to	  investigate	  the	  effects	  of	  HDACI	  on	  vitamin	  D-­‐induced	  gene	  expression.	  To	  study	  how	  histone	  deacetylase	  inhibitor	  influences	   VD/VDR–mediated	   gene	   expression,	   and	   to	   what	   extent	   histone	  deacetylase	   inhibitor	   can	   modulate	   the	   VD/VDR–mediated	   gene	   expression	   in	  preadipocytes,	  we	  examined	   the	   individual	  effect	  of	   two	  HDACIs,	  TSA	  and	  SFN,	  on	  CYP24	   mRNA	   expression.	   Our	   central	   hypothesis	   was	   that	   treatment	   of	   3T3-­‐L1	  mouse	   preadipocytes	   with	   either	   histone	   deacetylase	   inhibitor	   (tricostatin	   A	   or	  sulforaphane)	  would	  increase	  1,25(OH)2	  vitamin	  D-­‐induced	  CYP24	  mRNA	  levels.	  	  	   Our	   observations	   are	   consistent	   with	   the	   idea	   that	   both	   TSA	   and	   SFN	   can	  increase	   1,25(OH)2	   vitamin	   D-­‐induced	   CYP24	   mRNA	   expression	   in	   3T3-­‐L1	  preadipocytes	   (Figure	   12,	   13).	   This	   finding	   of	   up	   regulation	   of	   CYP24	   gene	  expression	   by	   TSA	   in	   preadipocytes	   is	   consistent	   with	   previous	   studies,	   which	  tested	   TSA	   in	   different	   cell	   lines,	   such	   as	   various	   prostate	   cancer	   cell	   lines	  (Gommersall	   et	   al.,	   2004b,	   Luo	   et	   al.,	   2010).	   To	   our	   knowledge,	   our	   observations	  concerning	  the	  effect	  of	  TSA	  in	  3T3-­‐L1	  mouse	  preadipocytes	  are	  novel	  and	  support	  the	   view	   that	   concomitant	   vitamin	   D	   and	   HDACI	   treatment	   could	   influence	   the	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effects	   of	   the	   vitamin	   D	   hormone	   on	   adipocyte	   biology.	   The	   dietary	   histone	  deacetylase	   inhibitor	   (HDACI)	   sulforaphane	   (SFN)	   is	   one	   of	   the	   biologically	   active	  compounds	   in	   the	   human	   diet	   and	   is	   present	   at	   high	   levels	   in	   some	   cruciferous	  vegetables,	  such	  as	  broccoli.	  SFN	  has	  received	  a	  great	  deal	  of	  attention	  because	  of	  its	  ability	   to	   inhibit	   histone	   deacetylase	   enzymes,	   which	   was	   identified	   in	   human	  embryonic	  kidney	  293	  (HEK293),	  HCT116	  human	  colon	  cancer	  cells	   (Myzak	  et	  al.,	  2004),	   and	  prostate	  epithelial	   cells	   (BPH-­‐1,	  LnCaP	  and	  PC-­‐3)	   (Myzak	  et	   al.,	   2006),	  and	  its	  potential	  use	  in	  cancer	  chemoprevention	  or	  treatment.	  	  Our	  novel	  observation	   that	   SFN	   increased	  vitamin	  D-­‐induced	  CYP24	  mRNA	  level	   in	   our	   3T3-­‐L1	   preadipocytes	   model	   system	   supports	   the	   idea	   that	   dietary	  consumption	   of	   foods	   containing	   bioactive	   food	   components	  with	   HDACI	   activity,	  such	  as	  certain	  cruciferous	  vegetables,	  may	  be	  able	  to	  affect	  adipogenesis	  by	  altering	  vitamin	   D-­‐induced	   gene	   expression.	   Adipogenesis	   in	   human	   primary	   adipocytes	  studied	  in	  culture	  has	  been	  recently	  reported	  to	  be	  increased	  by	  1,25(OH)2	  vitamin	  D	   [add	   reference	   from	   the	   BU	   group	   here].	   	   It	   is	   thus	   possible	   that	   HDACI	   could	  further	   increase	   the	   adipogenic	   response	   in	   humans	   to	   vitamin	  D	   compounds.	  On	  the	  other	  hand,	  there	  are	  studies	  that	  showed	  the	  inhibitory	  effect	  of	  TSA	  and	  SFN	  on	  adipogenesis	   in	   murine	   3T3-­‐L1	   preadipocytes	   (Lagace	   and	   Nachtigal,	   2004,	  Haberland	  et	  al.,	  2010,	  Choi	  et	  al.,	  2012).	  	  Additional	  studies	  are	  needed	  to	  investigate	  the	  influence	  of	  HDACIs	  on	  cell	  function	  because	  of	  the	  potential	  complex	  effects	  of	  these	  compounds.	  For	  example,	  an	   increase	   in	  CYP24	  expression	   induced	  by	  HDACIs	  could	  reduce	   the	   intracellular	  bioavailability	  of	  vitamin	  D	  metabolites	  because	  its	  main	  biochemical	  function	  is	  to	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initiate	  vitamin	  D	  catabolism	  and	  thereby	  reduce	  VDR	  signaling.	  The	  extent	  to	  which	  HDACIs,	   including	   SFN,	   affect	   other	   vitamin	   D-­‐dependent	   genes	   that	   may	   be	  involved	  with	  regulating	  adipocyte	  biology	  needs	  further	  exploration,	  as	  well	  as	  the	  net	   effect	   of	   HDACI-­‐induced	   effects	   on	   complex	   physiological	   processes,	   such	   as	  adipogenesis.	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CHAPTER	  6	  
FUTURE	  DIRECTIONS	  	  	   Although	  SFN	  treatment	  increased	  CYP24	  mRNA	  expression	  1.4-­‐fold	  at	  1nM	  1,25(OH)2	   vitamin	  D	   and	  nearly	  1.2-­‐fold	   at	   10	  nM	  1,25(OH)2	   vitamin	  D	   in	  3T3-­‐L1	  mouse	  preadipocytes,	   the	  main	  effect	  of	  SFN	  on	  CYP24	  mRNA	  was	  not	  statistically	  significant.	  	  Testing	  different	  concentrations	  of	  SFN	  would	  be	  helpful	  to	  understand	  the	  effect	  of	  SFN	  on	  CYP24	  mRNA	  expression.	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